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The adverse health consequences of air pollution are well recognized and range from minor 
upper respiratory system irritation to severe chronic lung disease.  The identity and mechanisms 
of these pollutants, as well as how toxicity is influenced by additional risk factors are unclear.  
This study elucidates the relationship between air pollution and microbial agents and explores the 
mechanisms by which the two stimuli interact to cause adverse health effects with important 
public health relevance.  Mycoplasma fermentans is a species of atypical bacteria with immune-
regulatory properties and potential to establish chronic latent infections.  Particulate matter (PM) 
is a complex and diverse component of air pollution associated with adverse health effects.  The 
hypothesis of this study is that M. fermentans infection modulates the cellular responses induced 
by exposure to residual oil fly ash (ROFA), a type of PM particularly rich in metals.  Using 
human lung fibroblasts (HLF) as an in vitro model I measured the release of the immune-
modulating cytokine interleukin-6 (IL-6) as a biomarker of stress-induced cell activation after 
exposure to various chemical and microbial challenges alone or together.   The synergistic 
interaction between live M. fermentans and ROFA to stimulate IL-6 release and gene expression 
in HLF was demonstrated.  This effect was specific for PM that contains high amounts of water-
 iii
soluble metal and was recapitulated when NiSO4 was substituted for ROFA.  The potentiating 
effect of live infection was mimicked by exposure to M. fermentans-derived macrophage- 
activating lipopeptide-2 (MALP-2), a Toll-like receptor-2 agonist.  Experiments with 
consecutive singular exposures to MALP-2 and NiSO4 revealed that pre-treatment of cells with 
NiSO4 facilitated MALP-2-induced IL-6 production, while pre-exposure to MALP-2 failed to 
influence the response to Ni.  Facilitation of MALP-2 response by NiSO4 depended, in part, upon 
Ni-induced activation of the ERK1/2 MAP kinase.  These interactive effects were studied at the 
level of gene transcription using a series of IL-6 promoter-luciferase reporter constructs and 
mutants.  
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1. INTRODUCTION 
 
1.1. MYCOPLASMA AND M. FERMENTANS 
Mycoplasma are a group of the smallest free-living and self-duplicating organisms with minute 
genomes (a total of about 500 to 2200 genes) (1).  They can infect plants and animals including 
humans.  Mycoplasma are not typical bacteria or viruses but a member of the mollicute family, 
having no cell wall, acting as virus-like infectious agents, and possessing complexity somewhere 
between viruses and bacteria.  Mycoplasma utilize the host’s machineries for enhanced 
replication and protein synthesis.  They can grow in tissue fluids or in viable tissue cell cultures 
with / without causing tissue cell damage or pathogenicity.  Therefore, mycoplasma may 
comprise a part of the normal mucosal flora of healthy persons, although blood, cerebrospinal, 
pleural, abdominal and joint fluids and bone from healthy persons are usually negative for 
mycoplasma.  Mycoplasma can also reside intracellularly, unlike common bacteria which 
typically exist extracellularly.  Thus, mycoplasma often evade detection by conventional 
laboratory diagnostic assays that use fluid samples.  As mycoplasma do not always trigger an 
elevated white blood cell count, systemic mycoplasma infection will not show on a routine 
complete blood count (CBC) used to determine elevated white blood cells typically associated 
with a bacterial infection.  In addition, they are difficult to detect by direct microbiological 
culture due to their slow growth and fastidious metabolic requirements.  One of the most useful 
distinguishing features of mycoplasma is their peculiar fried-egg colony shape, consisting of a 
central zone of growth embedded in the agar and a peripheral one on the agar surface (2).  The 
intracellular life cycle also allow these microorganisms to escape from the host’s immunological 
challenges.  Moreover, mycoplasma frequently alter their antigenic surface molecules and utilize 
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 molecular mimicry to avoid the immune surveillance.  Thus, these microbes are hard to detect 
and may be commonly present in human populations. 
 
It has been shown that seven different species of mycoplasma are associated with various 
infections in humans. They are M. pneumoniae, M. genitalium, Ureaplasma urealyticum, M. 
fermentans, M. pirum, M. hominis, and M. penetrans.  Mycoplasma infections have been 
implicated as causal triggering or complicating factors in many chronic illnesses including 
neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (3;4).  M. pneumoniae is the 
most common pathogen in lung infections among 5 to 35 year old patients.  Infection with this 
organism remains an important cause of pneumonia and other airway disorders such as 
tracheobronchitis, pharyngitis and chronic asthma (5-9).  This organism is also associated with 
extrapulmonary manifestations such as hematopoietic, joint, central nervous system, liver, 
pancreas and cardiovascular disorders (10-12).  M. genitalium, which was originally isolated 
from urethral specimens of two men with nongonococcal urethritis, could be involved in pelvic 
inflammatory disease (13-15).  Ureaplasma urealyticum is responsible for nonchlamydial, 
nongonococcal urethritis of males, meningitis in very-low-birth-weight infants, and 
chorioamnionitis (16;17).  M. pirum, M. hominis, and M. penetrans have been proposed as 
human pathogens and possible cofactors in HIV infection-associated diseases (18-20).  These 
organisms may contribute to the variation in the time from infection with HIV to the 
development of AIDS symptoms.  Therefore, several mycoplasma species are directly involved 
in the induction of pathological changes.  Unlike the above mentioned mycoplasma species, M. 
fermentans has been found in saliva and oropharyngeal of 45% of healthy adults and is 
considered to be a commensal in the human mucosal tissues.  Despite this high prevalence in 
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 healthy patients, this organism is associated with several human diseases, such as arthritis, 
chronic fatigue syndrome (21-24), fibromyalgia (25) and leukemia (26;27).  It was also proposed 
to act as a human pathogen and cofactor in HIV infection-associated disorders (28;29).  In 
addition, M. fermentans has been isolated from synovial tissues in patients with rheumatoid 
arthritis (30-32), which points to its possible implication in this clinical manifestation.  
Therefore, infection with M. fermentans may aggravate or facilitate pathological changes 
generated by other agents.  One of the well documented effects of M. fermentans is its capacity 
to stimulate immunocompetent cells to produce pro-inflammatory cytokines or in particular 
cases, to lead them to cell death (33).  Infection with M. fermentans also appears to inhibit 
enzymes, such as proteases and phospholipases and to increase production of oxygen radicals 
(33;34).  Taken together, infection with M. fermentans may participate with other factors in the 
pathogenesis of various diseases.  Yet, the molecular mechanisms underlying these effects 
remain uncertain.  
 
1.2. MALP-2 
The innate immune system relies on a vast array of pattern recognition receptors for the detection 
of pathogens.  Pattern recognition receptors such as toll-like receptors (TLRs), bind conserved 
molecular structures shared by large groups of pathogens, termed pathogen-associated molecular 
patterns (PAMPs).  PAMPs are conserved motifs that are unique to microorganisms and are 
essential for their metabolism and thus survival (35).  They have the following characteristics. 
First, PAMPs are produced only by microbes and not by host cells, enabling the innate immune 
system to distinguish between self and nonself.  Second, as PAMPs are essential for microbial 
survival, mutations in or loss of patterns can be lethal, and therefore these patterns are not subject 
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 to high mutation rates.  And third, PAMPs are invariant between microorganisms of a given 
class, which implies that only a limited number of germ line-encoded pattern recognition 
receptors are needed to detect the presence of a microbial infection (35).  Unlike most bacteria, 
mycoplasma have no cell wall, and thus their lipid bilayer membrane is the only structure that 
regulates the interaction with the external environment.  The Mollicutes membrane classically 
consists of two bi-lipid sheets and membrane proteins which include the integral membrane 
proteins and peripheral proteins.  Outer peripheral proteins, also named membrane lipoproteins, 
are thought to include the immuno-dominant antigens of mycoplasmas and to be directly 
involved in the interaction with host cells (36;37).  They are currently the subject of substantial 
interest because they are presumed to be involved in several important functions, such as 
interaction with host cells, invasion into host cells and avoidance of immune surveillance.  Crude 
lipoprotein extracts, purified lipopeptides or fatty components from mycoplasmas have all been 
demonstrated to stimulate the production of cytokines by monocytes and to induce B-cell 
proliferation (37-40).  Three forms of a mycoplasma lipopeptide / protein with the ability to 
modulate the host immune system were independently identified and named macrophage-
activating lipopeptide 2 (MALP-2), P48 and M161Ag (identical to MALP-404) (41).  Most 
lipoproteins extracted from bacteria are triacylated at the NH -terminal cysteine residue, 
molecular motif recognized by toll-like receptors (TLRs) 1 and 2.  In contrast, mycoplasma-
derived macrophage-activating lipopeptide 2 (MALP-2) is only diacylated.  It is a 
2
2-kDa 
lipopeptide originally isolated as an inducer of nitric oxide (NO) at picomolar concentrations 
from macrophages (39).  The amino acid sequence of MALP-2 is entirely consistent with the N-
terminal amino acid sequences of M161Ag and P48.  It is probably derived from the larger 
lipoprotein M161 Ag by posttranslational cleavage (40;42).   Studies shows that the amino acid 
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 sequence of MALP-2 is S-(2,3-bisacyloxypropyl) cysteine-GNNDESNISFKEK, with 1mol of 
C16:0 and a further mol of a mixture of C18:0 and C18:1 fatty acid per lipopeptide molecule (43).  In 
addition to its effect on NO, it induces chemoattractant mediators, such as macrophage 
inflammatory protein 1α and 2 (MIP-1α and 2) and monocyte chemoattractant protein 1 (MCP-1) 
in mouse and human cells (44).  MALP-2 exhibits potent endotoxin-like activity and its lethal 
toxicity is comparable to that of LPS (45).  Synthetic MALP-2 produces no oncogenic activity 
(43) and activates TLR2 and TLR6 due to its unique diacylated N-terminal (41;46-48).  
Coexpression of TLR2 and TLR6 is absolutely required for MALP-2 responsiveness because 
TLR2 and TLR6 cooperate to recognize MALP-2 and TLR6 appears to confer the ability to 
discriminate between the NH2-terminal lipoylated structures of MALP-2 from other lipopeptides 
derived from other bacteria (47). 
 
MALP-2 induces AP-1 and NF-κB activity and cytokine secretion in macrophages via the 
activation of mitogen-activated protein kinase (MAPK) pathways (49).   Its stimulatory effects 
on macrophages were fully comparable with those previously found with M. fermentans 
lipoproteins, suggesting that the lipopeptides derived from M. fermentans might constitute 
excellent tools for better understanding the immunomodulation and other pathogenic properties 
induced by these microorganisms.  
 
1.3. RESIDUAL OIL FLY ASH AND NICKEL  
Particulate matter (PM) is one of the six common air pollutants besides ozone, carbon monoxide, 
nitrogen dioxide, sulfur dioxide and lead that have air quality standards set by the United State 
EPA.  It is the term for particles found in the air, including dust, dirt, soot, smoke, and liquid 
droplets.  Particle size and composition varies widely according to their origin and generation 
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 process.  Some are directly emitted into the air from cars, trucks, buses, factories, construction 
sites and burning of wood, others may be formed in the air from the chemical conversion of 
gases.  Depending on the wind and particle size, they stay in the air for different periods of time 
and are spread to varying distances.  Particulate matter can be dividend into several levels 
according to their size.  Total suspended particles (TSP) are those with diameters less than 100 
µm, inhalable particles are also called PM10 since they are less than 10 µm in diameter, respirable 
particles (PM 2.5) have a diameter less than 2.5 µm  and ultrafine particles are smaller than 0.1µm 
in diameter (50).  Particles with a diameter of 2.5 µm or less are potentially more harmful than 
larger particles because they can travel over hundreds of miles from their origin and have 
relatively longer atmospheric lifetime than do larger particles.  They penetrate more readily into 
cells and through tissue barriers, have greater surface area per unit of mass (toxic reactions 
presumably occur at the surface) and dissolve more rapidly than do larger particles, thus 
enhancing the bioavailability of solubilized agents. 
 
In addition to particle size, particulate matter also can be categorized by its composition.  Two 
widely studied particulate matters are diesel exhaust particles (DEPs) and residual oil fly ash 
(ROFA).  DEPs are products of the combustion system of diesel engines and a known 
environmental pollutant.  It is a complex mixture of particulate materials primarily composed of 
black carbon, often referred to as elemental carbon, a soiling agent.  It also contains many 
organic compounds including polycyclic aromatic hydrocarbons (PAHs) that are potential 
carcinogens (51).  DEPs have larger surface areas, ranging from 30 to 100 m2 / g, on which a 
wide range of organic compounds are absorbed.  Nearly all DEPs fall within the PM2.5-size 
range, with mass median diameters ranging from 0.05 to 0.3 µm. (52).  ROFA is a combustion 
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 product of fuel oil.  Fly ash from fossil fuel combustion contributes more than 2.5 x105 tons 
annually to the ambient air PM burden in the United States.  Although size may vary with time, 
origin and other factors, ROFA is frequently less than 2.5 µm in diameter.  It consists of mostly 
inorganic materials with variable compositions depending on the fuel grade and temperature of 
combustion.  Compared to other ambient pollution particles, ROFA is chemically complex and 
includes sulfates, silicates, carbon-and nitrogen-containing compounds, contaminants of the fuel, 
and additives (53).  One of the outstanding characteristic of ROFA is that it is rich in transition 
metals, such as iron, zinc, magnesium, vanadium, copper and nickel (54;55).  Rich in metals, 
with little in the way of organic components, make it a particularly useful surrogate for ambient 
air PM to test how metals mediate the biologic effects of air pollution particles.  ROFA has been 
used in a number of in vitro and in vivo toxicologic studies (56-59).  The soluble transition 
metals (especially metal sulfates) play an important role in mediating biological effects of ROFA 
(60-64).  Copper ions may cause some of the biologic effects of inhaled particulate air pollution 
in the Provo region of the United States, and may provide an explanation for the sensitivity of 
asthmatic individuals to Provo particulates that has been observed in epidemiologic studies 
(65;66).  Some studies also found that vanadium, another transition metal rich in ROFA, 
mimicked the effects of intact ROFA for most of the production and release of inflammatory 
mediators by airway epithelial cells (60;67).  Potential mechanisms whereby ROFA induces its 
injurious effects may involve development of an oxidative burden generated by the high content 
of transition metals in ROFA and by depletion of antioxidant defenses in target cells and tissues.  
Thus, the oxidant-sensitive transcriptional factors such as nuclear factor κB (NF-κB ) and 
activator protein-1 (AP-1) can be activated (68;69).  In human airway epithelial cells, NF-κB was 
proposed to mediate the expression of interleukin-6 (IL-6) in response to ROFA exposure (70).  
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 Nickel is another transition metals found in ROFA released from power plants that is associated 
with adverse health effects. In the lower airways, nickel exposure is associated with 
immunological sensitization, epithelial dysplasia, asthma, lung cancer, and fibrosis (71-74).  At 
the cellular level, nickel stimulates signaling cascades in airway epithelium that increase 
expression of inflammatory cytokines like IL-8, the profibrotic gene, plasminogen activator 
inhibitor-1, and genes involved in hypoxic responses (75).  Also, the existence of multiple metals 
may provoke some synergistic effects on exposed cells (75). 
 
1.4. INTERLEUKIN-6  
IL-6 was first cloned during an effort to isolate and characterize the virus-induced protein 
interferon-β (76).  It belongs to the family of IL (interleukin)-6-type cytokines which comprises 
IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), CNTF (ciliary neurotrophic 
factor), CT-1 (cardiotrophin-1) and CLC (cardiotrophin-like cytokine) (77).  IL-6-type cytokines 
exert their action via the signal transducers gp130 (glycoprotein 130 KDa), LIF and OSM 
receptors leading to the activation of the JAK / STAT (Janus kinase / signal transducer and 
activator of transcription) and MAPK cascades (78;79).  IL-6 is well recognized for its role in the 
acute phase inflammatory response, which is characterized by production of a variety of hepatic 
proteins termed acute phase proteins (80).  In addition to its role in the acute phase response, IL-
6 is important for the development of specific immunologic responses.  It may be an important 
mediator of several infectious and autoimmune diseases (81-83).  These include human 
immunodeficiency virus, rheumatoid arthritis, Castleman's disease, and the paraneoplastic 
symptoms associated with cardiac myxoma (84-87).  IL-6 production has been documented in a 
seemingly endless variety of lymphoid and nonlymphoid cells, such as T-cell lines (88;89), B 
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 cells, fibroblasts (90), endothelial cells (91), keratinocytes (92), monoctes / macrophages (88;93), 
mast cells (94;95), and a variety of tumor cells lines (96).  Among the proinflammatory 
cytokines, IL-6 is considered to contribute to the initiation and extension of inflammatory 
process.  It may play a role in regulating the cellular recruitment in the lungs during an 
inflammatory response, with dramatic consequences for the cellular profile in the 
bronchoalveolar lavage and the subsequent fibrosis (97).  In vitro infection of human lung 
fibroblasts with M. fermentans represents a potent stimulus for the production of inflammatory 
cytokines IL-6 (98).  Recent studies also found that endogenous IL-6 plays a critical role in the 
progress of lung inflammation / injury associated with exposure to air pollutants in various 
animal and cell culture experiments (99-101).  Since IL-6 is considered a critical and interesting 
cytokine in inflammatory process, it has been used as a prototype cytokine to study the possible 
inflammatory response caused by M. fermentans and particulate matters by human lung 
fibroblasts. 
1.5 HYPOTHESIS 
Since simultaneous microbial and chemical stimuli would be commonplace in the real world 
situation, it is important to study the interaction between the two divergent stimuli.  Here, I 
hypothesize that microorganisms such as M. fermentans modulate cellular response to 
environmental stimuli such as atmospheric particulate matters to provoke an inflammatory 
response greater than the sum of the two stimuli.  Unfortunately, there is no well-established 
animal model for the study of M. fermentans infection, so in vitro approach using co-exposure to 
M .fermentans or its derived lipopeptide MALP-2 and particles is the main method used to 
investigate the interaction between those two stimuli.  To study the immune-modulating effect of 
M. fermentans, lung fibroblasts were used for the study instead of phagocytic bactericidal cells 
9 
 like macrophages in order to achieve a chronic infection.  Also, previous lab studies found that 
human lung fibroblasts isolated from lung transplant patients during the follow up phase have 
high M. fermentans infection rate.  Those infected cells released high amount of immune-
modulating cytokine such as IL-6 and tumor necrosis factor (TNF) (98) .  To further study the 
interaction between M. fermentans and PM, human lung fibroblasts were used and immune-
modulating cytokine IL-6 was measured as the endpoint. 
10 
 2. SPECIFIC AIMS 
 
The overall goal of this project is to characterize the synergistic interactions between M. 
fermentans and residual oil fly ash (ROFA) to amplify IL-6 production in human lung fibroblasts 
and identify the mechanism of this synergistic reaction. 
 
The specific aims of the project are: 
1) To establish and characterize the synergistic interaction of M. fermentans and ROFA to 
stimulate the production of the immune-modulating cytokine IL-6 by HLF.  
Human lung fibroblasts were deliberately infected or uninfected with M. fermentans and then 
exposed to ROFA fine particles at various concentrations.  IL-6 release was determined at 
various times following exposure to ROFA.  Particulate matters from various origins were 
compared for their ability to stimulate IL-6 release.  The ability of the M. fermentans-derived 
lipopeptide MALP-2 to substitute for live infection with the microorganism was tested.  Water 
soluble and insoluble fractions of ROFA, as well as a number of its known metal constituents, 
were compared for their ability to amplify IL-6 release. 
  
2) To explore the involvement of MAPK pathway in the IL-6 production by MALP-2 and NiSO4 
from HLF. 
Time course of NiSO4 and MALP-2 co-exposure suggested that one stimulus may facilitate the 
subsequent response to the other in producing IL-6.  A pre-treatment paradigm was used to test 
for conditioning effects of one compound to influence IL-6 release by the other chemical.  
MAPK pathway specific inhibitors were used to explore which pathways play an important role 
in regulating IL-6 production caused by NiSO4 and MALP-2.   NiSO4 was found to activate 
11 
 ERK1/2 and JNK in HLF and its facilitation effects on MALP-2 in producing IL-6 can be 
partially abolished by ERK1/2 but not JNK specific inhibitor.  ERK1/2 specific inhibitor 
PD98059 also partially abolishes IL-6 production by NiSO4 and MALP-2 co-exposure.  
 
 
3) To determine the effects of M. fermentans-derived macrophage activating-lipopeptide 
(MALP-2) and NiSO4 on IL-6 gene transcription.  
Luciferase reporter gene expression driven by the promoter region of human IL-6 promoter gene 
was used to determine transcriptional activation of the gene.  Site-directed mutagenesis was used 
to generate constructs that lacked binding sites for NF-κB, NF-IL6 or AP-1.  Treatment with 
NiSO4 and MALP-2 alone or in combination were used to test their ability to affect IL-6 
promoter activity. 
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 3. RESULTS 
3.1. Chapter 1 
Published in: 
Toxicological Sciences 81, 467-479 (2004) 
 
Microbial Stimulation by Mycoplasma fermentans Synergistically Amplifies IL-6 Release by 
Human Lung Fibroblasts in Response to Residual Oil Fly Ash (ROFA) and Nickel 
 
Fei Gao, Aaron Barchowsky, Antonia A. Nemec and James P. Fabisiak
 
Department of Environmental and Occupational Health, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, Pennsylvania 15260  
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 3.1.4. Abstract 
 
Mycoplasmas (MP), such as the species M. fermentans, possess remarkable immuno-regulatory 
properties and can potentially establish chronic latent infections with little signs of disease. 
Atmospheric particulate matter (PM) is a complex and diverse component of air pollution 
associated with adverse health effects.  We hypothesized that MP modulate the cellular responses 
induced by chemical stresses such as residual oil fly ash (ROFA), a type of PM rich in transition 
metals.  We assessed the release of interleukin-6 (IL-6), a prototypic immune-modulating 
cytokine, in response to PM from different sources in human lung fibroblasts (HLF) deliberately 
infected with M. fermentans.  We found that M. fermentans and ROFA together synergistically 
stimulated production of IL-6 compared to either stimulus alone.  Compared to several other PM, 
ROFA appeared most able to potentiate IL-6 release.  The potentiating effect of live MP 
infection could be mimicked by M. fermentans-derived macrophage-activating lipopeptide-2 
(MALP-2), a known Toll-like receptor-2 agonist.  The aqueous fraction of ROFA also contained 
potent IL-6 inducing activity in concert with MALP-2, and exposure to several defined metal 
salts indicated that Ni and, to a lesser extent V, (but not Cu) could synergistically act with 
MALP-2 to induce IL-6.  These data indicate that microorganisms like MP can interact with 
environmental stimuli such as PM-derived metals to synergistically activate signaling pathways 
that control lung cell cytokine production and, thus, can potentially modulate adverse health 
effects of PM exposure. 
Key Words: residual oil fly ash; mycoplasma; interleukin-6; particulate matter; MALP-2; human 
lung fibroblasts; nickel; transition metals; innate immunity; cytokines.  
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 3.1.5. Introduction  
 
Atmospheric particulate matter smaller than 10 µm (PM10) is listed as one of the six "criteria 
pollutants" for which the USA EPA has set air quality standards.  Epidemiological studies show 
that PM is associated with a variety of adverse health effects (102-105).  Particular matters arise 
through variety human and natural activities and thus give rise to a myriad of PM types of 
diverse chemical composition and physical properties.  While the biological effects of PM differ 
widely according to their size, composition, and quantity, certain entities including metals 
(60;67), organic aromatic hydrocarbons (106), and microbial-derived biomolecules (107) have all 
been specifically implicated in the toxic effects.  Numerous in vivo and in vitro studies reveal that 
PM exposure results in activation of inflammatory responses accompanied by elaboration of 
immune-modulating cytokines (108-110).  Residual oil fly ash (ROFA), a combustion product of 
fuel oil rich in transition metals, possesses potent biological effects (53) and has been useful as a 
model particulate to study how metals mediate the biologic effects of air pollution particles. 
 
Mycoplasmas (class Mollicutes) are a class of cell wall-free bacteria that represent the simplest 
self-replicating microorganisms known (111).  Due to their extremely small genome (0.58–2.20 
Mb) and their limited metabolic options for replication and survival, these fastidious 
microorganisms have adopted a strict parasitic lifestyle in intimate relationship with a variety of 
animal and human hosts.  With the exception of M. pneumoniae (112), these microorganisms are 
not usually considered severely pathogenic; however, they may modulate host defense 
mechanisms (113;114).  Mycoplasma spp. are commonly found on various mucosal surfaces of 
healthy individuals, however, systemic dissemination and opportunistic growth of these 
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 microorganisms has been detected in patients with a variety of chronic inflammatory conditions 
including asthma (9;115).  M. fermentans serves as a good example of these "stealth" pathogens 
(21;29;116-118). 
 
We have previously observed that several early passage fibroblast cell lines derived from human 
lung were infected with M. fermentans (98).  Infection induced production of immune-
modulating cytokines such as IL-6 and strongly potentiated the ability of known inducers such as 
TNF-ß.  Since exposure to PM, in general, and ROFA, in particular, can serve as potent stimuli 
for cytokine-dependent inflammatory responses in vitro and in vivo, we sought to test the 
hypothesis that M. fermentans exacerbates release of immune-modulatory factors induced by 
these chemical agents.  We used our model of human lung fibroblasts (HLF) deliberately infected 
with M. fermentans to examine the ability of various components of PM to induce the induction 
of a prototypic immuno-modulatory marker cytokine, IL-6.  M. fermentans and ROFA 
synergistically interacted to increase the production of IL-6.  These effects were mimicked with 
concurrent exposure to the Toll-like receptor-2 (TLR-2) agonist, M. fermentans-derived 
macrophage-activating lipopeptide-2 (MALP-2), and nickel.  Thus, exposure to microbial-
derived agents can strongly determine the cellular response to specific chemical stresses and 
warrants that the microbial ecology be taken into consideration in the risks and mechanisms of 
toxicity posed by atmospheric pollutants such as particulate-derived metals. 
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 3.1.6. Material and Methods 
 
Materials 
Cell culture medium, fetal bovine serum (FBS), and TRIzolTM were from Invitrogen 
(Gaithersburg, MD).  Tissue culture plasticware was from Falcon (Becton-Dickinson, Franklin 
Lakes, NJ).  SP-4 mycoplasma growth media (119) was formulated with mycoplasma broth base, 
peptone, tryptone, yeastolate, yeast extract (all from Becton-Dickinson Microbiological Systems, 
Sparks, MD), phenol red (Invitrogen), CMRL-1066 media, and Penicillin G (Sigma-Aldrich 
Chemical, St. Louis, MO).  Calf thymus DNA, Hoechst 33258, and various metal salts were from 
Sigma (St. Louis, MO).  Low endotoxin bovine-serum albumin (BSA) was from Intergen 
(Purchase, NY) and M. fermentans-derived macrophage-activating lipopeptide-2 (MALP-2) was 
from Alexis Biochemicals (San Diego, CA).  Bradford protein assay reagent was from Bio-Rad 
(Hercules, CA).  Murine leukemia reverse transcriptase, RNAse inhibitor, deoxynucleotides, 
oligo-dT and Taq DNA polymerase were from Promega (Madison, WI).  Preparations of PM 
were provided by Dr. Andrew Ghio, U.S. EPA. ROFA was collected by Southern Research 
Institute (Birmingham, AL) downstream from a cyclone scrubber at a power plant in FL burning 
a low sulfur #6 oil (120).  Other PM types included urban dust collected from Dusseldorf 
Germany (Dussel), volcanic ash from Mt. St. Helens (MSH), and an aqueous extract of PM 
collected from Provo Valley near Salt Lake City, Utah (SLC).  The chemical and physical 
characteristics of these particles have been described in detail (107;120-122).  The ROFA 
particles were devoid of endotoxin activity as measured by limulus amoebocyte assay.  
 
 
20 
 Cell culture 
Human lung fibroblasts (HLF) were isolated as outgrowths from explanted surplus transbronchial 
biopsy tissues obtained during routine follow-up bronchoscopy of lung transplant recipients as 
previously described (98) in accordance with a protocol approved by University of Pittsburgh 
Institutional Review Board.  The individual cell lines used here were recovered from frozen 
stocks prepared at passage three and used for experiments over no more than eight additional 
subcultures.  Greater than 95 % purity of fibroblasts was determined by positive 
immunohistochemical staining for vimentin and negative staining for cytokeratin A3 or Factor 
VIII.  Cells were maintained in Minimal Essential Medium (MEM) supplemented with FBS (10 
%, final concentration), glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 µg / ml), 
and Fungizone (1.25 µg / ml) in a humidified incubator at 37 °C with 5 % CO2 / 95 % air.  All 
cultures were negative for mycoplasma as determined by fluorescent microscopy using Hoechst 
33258 dye (123) prior to the deliberate introduction of M. fermentans.  
 
Isolation and culture of M. fermentans 
M. fermentans was isolated from previously described de novo infected HLF cell lines (98) by 
inoculating 50 ml of SP-4 media (119) with 10 ml of spent tissue culture medium obtained from 
MP-infected HLF.  Cultures were incubated in airtight flasks at 37 °C until a red to yellow color 
change was observed indicative of microbial growth.  Aliquots of MP cultures were 
cryopreserved by addition of 0.8 ml of culture to 0.2 ml glycerol and freezing at –80 °C.  The 
total amount of MP was quantified by fluorometric determination of DNA content using a 
modification of Hoechst 33258 assay (124).  The amount of viable organisms recovered from the 
frozen stocks was determined for each infection by determining the number of color changing 
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 units (ccu) measured with a limiting dilution assay (125).  The isolated strain of MP showed 
classical "fried-egg" morphology typical for the genus when grown on solid media and PCR 
positivity using M. fermentans sequence-specific primers (data not shown).  In addition, the M. 
fermentans species was verified using a species-specific monoclonal antibody. All experiments 
presented here utilized a single strain of M. fermentans derived from one infected cell line.  
 
In vitro infection with M. fermentans 
Uninfected HLF were seeded into T-75 flasks (6 x 105 cells / flask) and one P60 dish (2 x 105 
cells / dish) and incubated for 24 h. At the time of infection, MP was rapidly thawed, centrifuged 
12,000 x g for 15 min and washed twice with 0.25 M NaCl.  Final pellet was resuspended in 
complete tissue culture, and each T-75 flask and P60 dish received 450 ng or 150 ng of 
mycoplasma DNA, respectively.  Uninfected control cells were set up under identical conditions 
but did not receive mycoplasma and were maintained in a separate incubator.  At 4 days post-
infection cells were trypsinized, counted, and seeded into appropriate plates for experiments.  
Mycoplasma infection was verified by staining the P60 dish with Hoechst 33258 dye.  Based on 
organism load expressed as ccu / ml and DNA content these conditions represent the introduction 
of ~100 viable organisms and ~300 total organisms per cell.  
 
Cell viability 
Cell viability was measured by quantifying the reduction of the fluorogenic dye, Alamar Blue 
(Biosource, Camarillo, CA).  Briefly, MP-infected or uninfected cells were seeded into 24-well 
plates (4 x 104 / ml) and allowed to attach for 24 h.  Cells were then exposed to various 
concentrations of ROFA for 24 h.  Media was then removed, cells washed once with PBS, and 
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 media replaced with 0.9 ml serum-free MEM.  Alamar Blue (0.1 ml of a 10 % solution made in 
serum-free MEM) was then added to each well, and cells returned to the incubator for 3 h.  
Fluorescence in each well was measured using a Cytofluor 2300 fluorescence plate reader using 
excitation 530 ± 25 nm and emission 590 ± 25 nm.  
 
In vitro exposures and IL-6 measurement 
M. fermentans-infected cells and uninfected cells were seeded into either 6-well plates (3–4.5 x 
105 cells / 3 ml / well) or 24-well plates (0.6–1 x 105 cells / 1 ml / well) and cultured for 48 h.  
Media was removed and replaced with the same volume of serum-free media containing 0.1 % 
BSA with or without various stimuli.  Conditioned media was collected at indicated time points 
and stored at –80 °C until further analysis.  IL-6 content of conditioned media was measured 
using a specific enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, 
MN) according to the manufacturer's instructions.  For experiments in 6-well plates, IL-6 content 
was normalized to the producing cell number measured by nuclei counts obtained after lysis in 
0.1% citric acid / 0.1 % crystal violet (98).  For experiments in 24-well plates, IL-6 was 
normalized to the DNA content of the monolayer measured using Hoechst 33258 fluorescence 
(124).  
 
Measurement of cytokine mRNA 
Total cellular RNA was isolated using TRIzolTM reagent (Invitrogen, Gaithersburg, MD) 
according to the manufacturer's instructions.  cDNAs were generated from 0.5 µg total RNA by 
reverse transcription in a 30 µl reaction mixture containing Ambion 103 first strand buffer, 10 U 
RNase inhibitor, 0.33 mM each dNTP, 1.7 mM oligo dT, and 100 U M-MLV reverse 
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 transcriptase.  Reactions were incubated at 44 °C for 60 min in a MJ Research PTC-100 
thermocycler.  cDNA was stored at –20°C until further analysis.  Specific primer pairs for IL-6 
(forward 5'-GCCCAGCTATGAACTCCTTCTC; reverse 5'-GACTTGTCATGTCCTGCAGCC), 
IL-8 (forward 5'-ATGACTTCCAAGCTGGCCGTGGCT; reverse 5'-
TCTCAGCCCTCTTCAAAAACTTCTC) and ß-actin (forward 5'-
GGGACCTGACCGACTACCTC; reverse 5'-GGGCGATGATCTTGATCTTC) were used to 
amplify the specific cDNAs.  Specific cDNAs were amplified using 5 µl aliquots cDNA mixed 
with 1.25 µl of IL-6, IL-8, or ß-actin forward and reverse primers, 2.5 U of Taq DNA 
polymerase, and 0.125 mM dNTP in Ambion complete PCR buffer in a final volume of 50 µl.  
PCR reactions were carried out for 20 s at 95 °C, 30 s at 55 °C, and 40 s at 72 °C for 19 cycles 
for ß-actin or 24 cycles IL-6 and IL-8.  The number of cycles was demonstrated to be within the 
linear amplification range for each product.  PCR products were either detected on 2 % agarose 
gels stained with ethidium bromide or quantified in real-time fashion during the PCR 
amplification using the double-strand DNA fluorescent dye PicoGreen at 430 nm emission and 
525 nm excitation.  IL-8 and IL-6 mRNA expression were normalized to the housekeeping gene 
ß-actin by determining the ratio of the IL-8 or IL-6 fluorescent signals to that for ß-actin.  
 
Statistical analysis 
Data presented are expressed as mean ± SEM collected from at least three or four individual 
experiments for studies employing pooled HLF or cells derived from individual donors, 
respectively.  Comparisons were made using a one-way ANOVA followed by appropriate group 
comparisons such as Dunnett's multiple comparison to control or Bonferonni's correction for 
multiple t-tests.  Significance of response to a range of concentrations to single agents was 
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 determined by a test for linear trend across the applied concentrations.  To control for variability 
between multiple individually derived cell lines repeated measures ANOVA and post hoc tests 
were applied with pairing of data collected within a specific cell line.  When variability between 
cell lines precluded the assumption of a normal distribution, nonparametric Wilcoxon signed rank 
tests were used to compare groups.  To compare observed dose-response relationships with 
combined stimuli to a theoretical additive model, concentrations were transformed to log scale, 
and a predicted additive response was derived as the algebraic sum to similar concentrations of 
each agent alone.  Log–dose response curves were subjected to linear regression and the slopes 
compared by analysis of covariance.  Statistical analyses were performed using GraphPad 
PRISMTM, version 3.0 (GraphPad TM Software, San Diego, CA), and differences were considered 
significant at the p < 0.05. 
 
3.1.7. Results  
 
M. fermentans and ROFA Synergistically Stimulate IL-6 Release from HLFs 
 
To explore possible interactions between ROFA and Mycoplasma fermentans (MP), I first 
exposed MP-infected and uninfected HLF to various concentrations of ROFA for 24 h.  
Production of the immune-modulating cytokine IL-6 during this period was then measured (Fig. 
1).  In the absence of ROFA, IL-6 release in uninfected cells were 54 ± 11 pg / 105 cells and 
about 5-fold greater in cells infected with MP (445 ± 127 pg / 105 cells).  Exposure of uninfected 
cells to ROFA alone produced a dose-dependent increase in IL-6 release that, at the highest dose 
tested (603 ± 141 pg / 105 cells at 50 µg ROFA / ml), approximated that seen in the presence of 
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 MP alone.  When MP-infected cells were exposed to ROFA, however, the response was 
dramatically enhanced even at the lowest concentration of ROFA used (2 µg / ml), with IL-6 
production ranging from 21 to 50 times greater than the basal production seen in uninfected cells.  
In order to more clearly characterize the synergistic nature of this interaction, the observed dose-
response curve to ROFA in MP-infected cells was compared to that predicted by an additive 
model for these two stimuli (IL-6 release from MP alone + IL-6 released by each concentration of 
ROFA applied to uninfected cells). Figure 1B shows the observed and predicted log–dose 
response curves.  Linear regression of each line was performed and comparison revealed a highly 
significant difference between the slopes of the observed and predicted lines (p < 0.02).  Thus, 
the observed response to ROFA plus MP was always greater than that predicted in an additive 
model, and this difference grew in magnitude as the concentration of ROFA increased.  This 
represents a synergistic interaction between these two stimuli.  
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Figure 1:  M. fermentans synergistically amplifies the ability of ROFA to induce IL-6 production in human 
lung fibroblasts (HLF).  
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 I also measured the viability of HLF after exposure using the vital reduction of Alamar Blue.  
The LD50 was approximately 100 µg / ml and did not appear to be altered by MP-infection, nor 
was it influenced by the presence or absence of 10 % FBS during the ROFA exposure period 
(data not shown).  The observed LD50 was considerably higher than concentrations sufficient to 
produce a synergistic effect of IL-6 production (Fig. 1).  Thus, the synergistic interactions 
between ROFA and MP on induction of IL-6 production do not occur in the context of 
differential sensitivities to the overall toxic effects of ROFA. 
 
Comparison of ROFA to PM from Other Sources 
 
I next examined whether other types of PM might similarly augment IL-6 release from MP-
infected cells.  I measured IL-6 release during a 24-hour exposure of MP-infected and control 
uninfected HLF to equivalent concentrations (20 µg / ml) of urban dust collected from 
Dusseldorf, Germany (Dussel); aqueous extract of PM obtained from Provo Valley near Salt 
Lake City, Utah (SLC); Mt. St. Helens volcanic ash (MSH); as well as ROFA.  Figure 2A shows 
that 20 µg / ml ROFA significantly increased IL-6 release about four-fold above that seen in 
untreated uninfected cells.  In contrast, PM derived from other sources had little effect on IL-6 
release at this same concentration.  The slight increase observed with SLC did not reach 
statistical significance.  When these same exposures were carried out on MP-infected cells, it was 
again observed that the combination of ROFA nearly tripled the release of IL-6 relative to 
untreated MP-infected cells alone (Fig. 2B).  In keeping with the synergistic response, it is 
important to note that the amount of IL-6 release seen with the combination of ROFA plus MP is 
nearly 20-fold and 100-fold greater than that seen in uninfected cells in the presence and absence 
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 of ROFA, respectively.  Figure 2B also shows that the other PM types at this concentration 
lacked sufficient ability to induce IL-6 in MP-infected cells similar to uninfected cells.  Thus, the 
observed potency of ROFA to induce IL-6 release and interact with MP appears to arise from 
some unique property of this PM or relative enrichment of some chemical component compared 
to other PM.  
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Figure 2:  Comparison of various PM types on IL-6 production in control and MP-infected HLF. Uninfected 
control (panel A) and M. fermentans infected cells (panel B) were exposed to various PM types.  
 
 
M. fermentans-Derived 2 kDa Lipopeptide (MALP-2) Mimics the Effect of M. fermentans to 
Synergistically Interact with ROFA and Stimulate IL-6 Release 
 
I next sought to further define the signaling pathways that might be involved in IL-6 production 
during live infection with MP and hypothesized that activation of innate immune responses via 
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 activation of specific Toll-like receptor pathways could play a role.  Activation of TLR-4 initiates 
the well-described induction of inflammatory cytokines by macrophages and other cells in 
response to lipopolysacharide (LPS) derived from gram-negative bacteria cell walls.  
Mycoplasma, however, lack a characteristic cell wall and hence are devoid of endotoxin.  Several 
reports demonstrated that membrane lipoproteins derived from M. fermentans exhibit 
macrophage-stimulatory activities and induce the production of proinflammatory cytokines 
(43;126).  Macrophage-activating lipopeptide-2 (MALP-2), a 14 amino acid N-terminal fragment 
containing a unique diacylated cysteine, has been characterized and shown to induce the 
production of proinflammatory cytokines, as well as nitric oxide, via specific interaction with 
TLR-2 and TLR-6 (42;48).  I wondered if MALP-2 could recapitulate the effects of live infection 
and synergistically interact with ROFA to induce cytokine release.  To test this possibility, I 
exposed HLFs to various concentrations of MALP-2 in the presence and absence of ROFA (40 
µg / ml).  Conditioned media was collected after both 24 h exposure (Fig. 3A) and 48 h exposure 
(Fig. 3B) and analyzed for IL-6 content.  Exposure of HLF to MALP-2 alone induced a moderate 
concentration-dependent increase in IL-6.  The effect of MALP-2 alone was first observed at 300 
pg / ml and was further increased at 600 pg / ml.  The amount of cytokine released relative to 
unstimulated cells after 48 h exposure to the highest concentration of MALP-2 alone (385 ± 277 
with MALP-2 vs. 9 ± 4 pg / µg DNA unstimulated) was approximately 2-fold higher than that 
observed after only 24 h (150 ± 105 vs. 4 ± 1 pg / µg DNA), suggesting a fairly linear increase in 
IL-6 accumulation within the medium over this time.  ROFA itself in the absence of MALP-2 
had a very minimal effect on IL-6 release that reached 11 ± 4 and 45 ± 21 at the 24 (Fig. 3A) and 
48 (Fig. 3B) hour time points, respectively.  The inclusion of MALP-2 in combination with 
ROFA, however, markedly stimulated the release of IL-6.  The between cell line variability was 
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 sufficiently high to preclude a normal distribution of our data points.  At each concentration of 
MALP-2, however, each of the six cell lines tested showed an enhanced response to combination 
of ROFA and MALP-2 (p < 0.05, Wilcoxon's signed rank test).  At 24 h (Figs. 3A) and 48 h 
(Figs. 3B), the highest concentration of MALP-2 (600 pg / ml) in combination with ROFA 
released three to six fold more IL-6, respectively, compared to the same concentration of MALP-
2 alone.  I also compared the observed MALP-2 + ROFA response to values predicted by an 
additive model by summing the responses seen to ROFA alone and MALP-2 alone for each cell 
line (dotted lines in Fig. 3A and 3B).  At both time points the response observed with both 300 
and 600 pg / ml MALP-2 in combination with ROFA was significantly more than predicted from 
an additive model.  To further demonstrate the synergistic nature of these interactions, I analyzed 
log–dose response relationships by linear regression using those concentrations of MALP-2 
having a demonstrable effect (100–600 pg / ml) (Fig. 3A and 3B, insets).  The slope of the 
observed response to MALP-2 plus ROFA was three-fold and seven-fold greater at the 24 and 48 
h time points, respectively, compared to that predicted by an additive model; thus it is clear that 
the addition of ROFA dramatically synergized the effect of MALP-2 to induce IL-6. 
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Figure 3:  M. fermentans-derived macrophage activating peptide (MALP-2) and ROFA synergistically 
stimulate IL-6 release from HLF.  
 
The Effect of ROFA Is Mimicked by Its Water-Soluble Fraction and Specific Metal 
Constituents 
 
Airborne products derived from the combustion of fossil fuels are complex mixtures containing 
an elemental carbon core with adsorbed organic hydrocarbons and various metal salts and oxides 
depending on the origin of the fuel.  ROFA is extremely rich in its metal content, most notably 
vanadium (V), iron (Fe), and nickel (Ni), among others.  Many studies have implied that ROFA's 
soluble metallic components are responsible for its bioactivity.  To first evaluate the effect of 
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 soluble components in ROFA, we prepared a standard solution of ROFA particles in serum-free 
tissue culture media as used in the experiments described above.  Half of this mixture was 
filtered through a 0.22 µm filter to essentially obtain an aqueous extract of ROFA.  I exposed 
HLF to either untreated ROFA (20 and 40 µg / ml) or the soluble fraction corresponding to the 
same amounts of whole ROFA.  Table 1 shows the IL-6 response to soluble ROFA (filtrate) and 
total ROFA in the presence and absence of MALP-2 (600 pg / ml) after treatment for 24 and 48 
h.  As expected, exposure of the cells to ROFA or MALP-2 alone has very minimal effects of IL-
6 release at either time point.  When cells were exposed to the lowest concentration of total or 
soluble ROFA in combination with MALP-2 there was no enhancement at the 24 h time point, 
but by 48 h cells exposed to either total ROFA or soluble ROFA in the presence of MALP-2 
released approximately ten-fold more IL-6 than cells exposed to any stimulus alone.  With this 
small number of observations the response observed with 20 µg / ml ROFA filtrate plus MALP-2 
failed to reach statistical significance, however; no significant difference was detected compared 
to the response seen with the same concentration of total ROFA plus MALP-2.  When a higher 
concentration of ROFA (40 µg / ml) was used, significant synergy was observed between 
MALP-2 and total ROFA at both time points.  The response seen with 40 µg / ml ROFA filtrate 
plus MALP-2 was about 50 % and 75 % of that seen with total ROFA plus MALP-2 at the 24 
and 48 h time points, respectively.  Thus, these results show that soluble components of ROFA 
can synergistically interact with MALP-2 in producing IL-6 in a manner similar to that seen with 
exposure of HLF to the entire particle.  Although the synergy seen with ROFA filtrate is slightly 
weaker than ROFA as a whole, there is no statistically significant difference between intact 
ROFA and its soluble components.  
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 Table 1:  Water-Soluble Components of ROFA Mimic the Intact Particle to Induce IL-6 in HLF in the Presence of 
MALP-2 
 
 
33 
  
Since ROFA's soluble metallic components may be responsible for this synergy, I next sought to 
define which metal elements found in ROFA might alone synergize with MALP-2 to induce IL-6 
release from HLFs.  The ROFA preparation used in the previous experiments contains high 
levels of vanadium, nickel, iron, and copper.  Therefore, I first treated HLFs with three 
concentrations of various metallic salts in the presence or absence of 600 pg / ml MALP-2 (Fig. 
4).  The most dramatic interaction for stimulation of IL-6 production was seen with NiSO4 and 
MALP-2.  Exposure of HLF to 200 µM NiSO4 by itself produced about a ten-fold increase in IL-
6 production and was about the same magnitude as that seen with MALP-2 alone.  The 
combination of MALP-2 along with 200 µM Ni, however, stimulated IL-6 release to a level over 
5 times that seen with either stimulus alone and over 50 times greater than that observed in 
unstimulated cells.  Exposure of cells to lower concentrations of Ni alone (2 and 20 µM) was 
ineffective and did not modulate the response to MALP-2.  Exposures of HLF to similar 
concentrations of CuSO4 had no stimulatory effect by themselves and, in fact, decreased the 
response to MALP-2 alone.  The two vanadium compounds, vanadyl (V4+) sulfate (VOSO4) and 
sodium vanadate (V5+) (Na3VO4) induced small increases in cytokine production when applied at 
200 µM in the absence of MALP-2 that were similar to that seen with the same concentration of 
Ni alone.  While the addition of MALP-2 to 200 µM Na3VO4 further increased IL-6 release, the 
observed response appeared was much less than that observed with Ni + MALP-2.  The response 
to 200 µM VOSO4 in combination with MALP-2 appeared only slightly greater than the additive 
effects of each stimulus alone and also was substantially less than that seen with nickel. 
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Figure 4:  Effect of several soluble metal salts on IL-6 release in the presence and absence of MALP-2.  
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To explore the dose-response relationships of Ni in more detail and further demonstrate the 
synergistic relationship between NiSO4 and MALP-2, I treated HLFs with various concentrations 
of NiSO4 between 20 and 200 µM in the presence or absence of 600 pg / ml MALP-2 (Fig. 5).  
The effects of nickel alone were extremely small, with IL-6 release remaining below 100 pg / µg 
DNA at the highest concentration for both the 24 h (Fig. 5A) and 48 h (Fig. 5B) time points.  
NiSO4, however, dramatically increased IL-6 release in a dose-dependent manner in the presence 
of MALP-2 to a level that was ten times that seen with MALP-2 or the highest concentration of 
Ni alone.  At the 48 h time point in the presence of MALP-2, even the lowest concentration of Ni 
provided enhancement over 20 µM Ni alone (101 ± 19 vs. 6.1 ± 0.7 pg IL-6 / µg DNA) and was 
nearly twice that predicted from an additive model (62.3 ± 11.7 pg IL-6 / µg DNA).  The 
synergistic interaction between Ni and MALP-2 was apparent when the slope of the observed 
dose-response to Ni plus MALP-2 was compared to that predicted by adding the observed 
responses to each agent alone, where the slope of the observed response was ten-fold greater than 
that predicted by an additive model.  Thus, soluble nickel ions may be one of the primary 
components in ROFA capable of synergistically interacting with MALP-2 to stimulate IL-6 
production from HLF. 
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Figure 5:  NiSO4 and MALP-2 synergistically stimulate IL-6 release from HLF. IL-6 was measured at both 24 
(panel A) and 48 h (panel B) after exposure.  
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 The effects of ROFA and Ni were further investigated at the level of cytokine mRNA and 
compared for their ability to modulate gene expression of IL-6 and another cytokine, interleukin-
8 (IL-8).  IL-8 is a potent inflammatory cytokine with neutrophil chemotactic activity whose 
regulation shares many similarities to that of IL-6.  The steady-state levels of both IL-6 and IL-8 
mRNA in HLF were measured after 24 h stimulation with Ni (200 µM) or ROFA (40 µg / ml) in 
the presence or absence of MALP-2 using RT-PCR, and ß-actin gene expression was assessed as 
a control.  Figure 6A shows a representative experiment and the specific ethidium bromide-
stained PCR products obtained after agarose gel electrophoresis.  Note that both IL-6 and IL-8 
transcripts were barely detectable in unstimulated cells.  Increased expression of IL-6 and IL-8 
was observed after 24 h treatment with either NiSO4 or ROFA alone and was similar in 
magnitude to that seen after MALP-2 alone.  The combinations of MALP-2 / ROFA or MALP-2 
/ NiSO4, however, produced a dramatic accumulation of mRNA for both cytokines that was 
much greater than that seen with any single agent alone.  The level of each cytokine mRNA 
species was measured using quantitative real-time RT-PCR, normalized to the amount of ß-actin 
transcript, and then compared between each treatment (Figs. 6B and 6C).  The steady-state level 
of IL-6 mRNA was induced about ten-fold above unstimulated control when cells were exposed 
to any of the stimuli as single agents; in contrast, the abundance of IL-6 transcripts were 
approximately 50-fold greater with the combinations of MALP-2 + ROFA and MALP-2 + 
NiSO4. A similar pattern of induction was also seen for IL-8, although the difference between 
MALP-2 + NiSO4 and NiSO4 alone just failed to reach statistical significance, in part, because of 
the unequal variances between the combination and single-stimuli exposure groups. 
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Figure 6:  Effects of MALP-2 plus ROFA or NiSO4 on steady-state level of IL-6 and IL-8 mRNA.   
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 3.1.8. Discussion 
 
This study is the first to observe a potent and significant interaction between a particular PM, 
ROFA, and exposure to the microorganism, M. fermentans.  Using IL-6, a prototypic immune-
modulating cytokine, as a biomarker for cellular activation of inflammatory responses, I 
demonstrate that levels of chemical stress and microbial stimulation that produce minimal 
response alone produce profound cell-activating effects when applied together.  These 
interactions are clearly synergistic since, (1) the observed response to simultaneous chemical and 
microbial exposure is greater than that predicted by the algebraic sum of each stimulus alone, and 
(2) the shape and slope of the dose-response curves to each agent can be reciprocally modulated 
by minimally-effective concentrations of the other. 
 
Dose-response relationships determined in specific pathogen-free animals and sterile cell culture 
models are often used to set risk assessment guidelines for various environmental agents.  This 
rarely, however, mimics relevant "real-life" exposures, where individuals may be exposed in the 
presence of microbial infection/colonization.  Such infection can range from clinically evident 
disease (pneumonia, tracheobronchitis), to subclinical latent chronic infection, to colonization 
with various "harmless" commensals.  Moreover, ambient PM itself is a complex mixture that 
contains particulates from many sources, including those of biological origin.  In fact, bacterial 
endotoxin and other microbial products have been implicated in some of the biological activity of 
ambient PMs (109).  Thus, the synergistic interactions between different components of the PM 
mixture and concurrent presence of microorganisms need to be considered when evaluating their 
overall toxicity. 
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 M. fermentans, serves as an example of a mycoplasma with potential to establish chronic 
subclinical infection.  Originally isolated from the genitourinary tract (127), M. fermentans has 
also been documented in joint fluid of patients with rheumatoid arthritis but not those with other 
arthrides (32;118), leukemic bone marrow (128), and a disproportionately high percentage of 
blood samples from those with chronic fatigue syndrome (21).  Recently, Mycoplasma spp. were 
detected in the airways of humans in absence of symptoms of acute infection, and the incidence 
was greater in asthmatics (9).  Using sensitive PCR-based detection methods, high incidences of 
M. fermentans positivity have been noted in saliva (116), blood (29), and urine (129) from 
apparently normal healthy subjects.  Data regarding the presence of M. fermentans within the 
human lung or its ability to establish chronic "symptomless" pulmonary infection, however, are 
severely limited. 
 
It remains unresolved as to what particular components of PM contribute to its adverse health 
effects.  ROFA is frequently used as a surrogate to study the adverse effects of PM, particularly 
in the context of particulate-derived metal (53); however, it represents a very small component of 
total air PM and does not accurately reflect the complex composition of ambient particulate 
mixtures.  Several studies have pointed to the importance of the "fine" (<2.5 µm) and "ultrafine" 
(<0.1 µm) fractions in mediating ambient PM toxicity (130;131).  Although these size fractions 
represent only <50 % and <10 %, respectively, of the total mass fraction of PM10, these fractions 
are enriched in their metal content.  Multiple sources of PM-derived metals exist in addition to 
ROFA.  Whether ambient PMs are capable of interacting with microbial stimuli in a manner 
analogous to ROFA will undoubtedly depend on their sources, chemical composition, size 
distribution, and physical properties. 
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 The ability of ROFA to produce cell and tissue injury and stimulate inflammatory cytokines has 
been linked to its high metal content (60;67;132;133).  In much the same way, our data support a 
role for particulate-derived metal in mediating the synergistic effects with MP.  Vanadium and 
iron have been implicated as the primary transition metals in ROFA capable of inducing 
oxidative stress and activating inflammatory responses such as cytokine release.  In contrast, my 
data point to an important role for Ni in mediating the effects observed here.  The preparation of 
ROFA used here contains 37.5 mg Ni/gm, which if completely soluble would produce from 6 to 
25 µM Ni with the ROFA concentrations used in Figure 1 (10–40 µg / ml).  It should be pointed 
out, however, that the threshold for the effect of NiSO4 was between 20 and 50 µM; therefore, it 
is likely that other metals or alternate forms of Ni also participate in the overall effects of ROFA.  
Ni is most often considered as an occupational hazard in exposed workers (74), although 
considerable exposure does occur in the general population, often in the form of ultrafine metal-
rich combustion-derived PM. Nearly 1 million to 200 million people living in the vicinity of Ni-
emitting sources are exposed to median concentrations of 200 and 50 ng Ni / m3 respectively 
(134).  Assuming an ambient level of 100 ng / m3, 50 % deposition, negligible elimination, and 
normal respiration, we estimate a daily dose of 864 ng Ni that if uniformly distributed within the 
noncellular volume of the lung (22 ml) would produce ≈1 µM Ni.  While this value is below that 
necessary to produce synergy, a small change in breathing parameters, potential for uneven 
distribution, and possible accumulation over time could produce Ni levels closer to those used in 
our experiments.  Using data from the Six Cities studies, Laden et al. (131) demonstrated that Ni 
was positively associated with daily deaths.  In animal studies, Ni synergistically interacts with V 
to initiate untoward cardio-vascular effects following inhalational exposure (63). 
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 My data do not speak directly to the cellular and molecular mechanisms that account for the 
synergistic interactions between ROFA and MP.  Since ROFA contains a variety of transition 
metals (Fe, V, Ni, among others) it is possible that enhanced formation of reactive oxygen 
species (ROS) during metal and microbial exposure can subsequently modulate signal 
transduction pathways culminating in IL-6 release.  The SLC PM, however, was inhibitory 
towards MALP-2-induced IL-6 despite the fact that this PM is particularly rich in redox-active 
Cu (65).  Although Ni leads to formation of ROS (135-137) it is not considered as redox-active 
as other transition metals.  It is possible, however, that Ni coordinated to specific ligands 
enhances its redox activity (137;138) and / or imparts an intracellular regio-specificity that is 
critical for these effects. 
 
Numerous transcription factors such as NF-κB and AP-1 play well-established roles in the 
regulation of cytokine gene expression following diverse microbial and chemical stressors. 
Activation of these pathways by ROFA (70;139) and MALP-2 (140) can occur through activation 
of protein kinase-dependent and oxidant-sensitive mechanisms. Other mechanisms of Ni-
dependent regulated gene expression include stabilization of hypoxia-inducible factor (HIF-1α) 
(141), as well as other novel, as yet defined, transcription factors (142).  Other possibilities for 
mechanisms of regulation-include metal-dependent inactivation of specific signal-transducing 
protein tyrosine phosphatases (133;143) and modulation of mRNA stability (144).  Thus, it is 
possible that synergy arises via amplified activation of one or more of these specific transcription 
factors or signaling pathways or, alternatively, that each stimulus produces a unique profile of 
signaling events that converge to govern gene expression in an interactive way. 
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 HLF are useful as in vitro model for these studies since they (1) support live MP infection, (2) 
represent a relatively normal untransformed human lung cell type without artifacts of prolonged 
tissue culture, and (3) play an active role in the cytokine and fibrotic response following tissue 
injury.  Other cells such as macrophages and epithelial cells, however, may arguably be more 
relevant since they are amongst the first to encounter PM and infectious stimuli.  Since regulation 
of cytokine production in diverse cell types likely follows common mechanisms, I anticipate that 
microbial stimuli and particulate-derived metals will similarly interact to activate other cell types 
within the lung. 
 
In summary, my studies demonstrate the potential for profound synergistic interactions between 
microbial products and PM in the ability of HLF to produce immune-modulating / inflammatory 
cytokines.  These effects occur in absence of cytotoxicity and with concentrations of stimuli that 
produce minimal effects by themselves.  Since it appears that mycoplasma are signaling through 
TLR-dependent mechanisms, the phenomenon can likely be extended to a range of diverse 
microorganisms.  My studies provide an experimental model to further examine the cellular and 
molecular mechanisms by which these microbial and chemical stimuli interact to modulate the 
expression of immune-modulating cytokines and other gene products important in the response to 
various environmental stresses. 
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 3.2. Chapter 2 
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MEK / ERK1/2 MAP kinase pathway is involved in the synergistic stimulation of IL-6 cytokine 
production by nickel sulfate and MALP-2. 
 
Fei Gao and James P. Fabisiak
 
Department of Environmental and Occupational Health, Graduate School of Public Health, 
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 3.2.1. Abstract 
 
Exposure to nickel sulfate (NiSO4) causes dramatic IL-6 release by human lung fibroblasts 
(HLFs) in combination with M. fermentans-derived macrophage-activating lipopeptide-2 
(MALP-2).  The mechanisms however for these effects are not well understood.  Therefore, cell 
culture experiments with HLFs were conducted to identify pathways involved in the synergistic 
interaction between MALP-2 and NiSO4.  This study found that MALP-2 and NiSO4 co-
exposure induces both IL-6 mRNA and protein production primarily at later time points 
suggesting that one stimulus potentiates the effect of another.  Pre-treatment of cell with NiSO4 
alone facilitates subsequent MALP-2-induced IL-6 production and this facilitation effect is 
partially blocked by PD98059, a specific inhibitor of the MAP Kinase MEK / ERK1/2 pathway.  
Western blot analysis shows that NiSO4 alone caused both ERK1/2 and JNK phosphorylation at 
about 10 minutes post-exposure and tapered away after 1 hour.  Further study found that 
MEK/ERK inhibitor PD98059 but not JNK inhibitor SP600125 partially abolished the synergy 
between MALP-2 and NiSO4 co-treatment in IL-6 production at both the protein and mRNA 
level.  These findings support the idea that the MEK/ERK1/2 pathway but not JNK activation 
induced by NiSO4 plays a role in the synergistic production of IL-6 in HLF. 
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 3.2.2. Introduction 
 
Inhalational exposure to airborne particulate matter (PM), even at ambient levels, has been 
linked to multiple adverse respiratory and cardiovascular health consequences including 
premature death.  Although current regulations and environmental controls have substantially 
reduced the atmospheric release of larger mass fractions, amounts of PM of smaller size (less 
than 2.5 µm) remains high.  These fine particulates are considered especially hazardous since a 
higher percentage of fine particulates are retained in the lung compared to larger particulates 
(145).  Moreover, PM2.5 and “ultrafines” contain the highest content of a variety of heavy metal 
toxins compared to larger particulate fractions.  Fugitive fly ash derived from the combustion 
residual fuel oil (residual oil fly ash, ROFA) is now widely used as a surrogate to study the 
biological effects on metal-containing atmospheric particulates.  The exposure to ROFA 
produces significant injury of airways and lungs.  While devoid of significant amounts of organic 
components, ROFA does contain relatively high quantities of transition metals, such as iron (Fe) 
and vanadium (V) mostly in the form of soluble sulfates, and these are often implicated in the 
acute toxicity of ROFA (53;132).  It is clear from numerous animal and in vitro studies that the 
toxicity from ROFA, as well as other PM, involves initiation of inflammatory responses within 
the lung; however the precise cellular and molecular mechanisms regulating the changes in gene 
expression that underlie these toxic pulmonary effects are still not completely understood.  
Activation of multiple stress-induced signal transduction pathways and transcription factors, in 
part through metal-catalyzed oxidative stress, have been demonstrated in many studies (146-
148). 
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 Numerous other metal species are also present in ROFA, even though the relative amount of 
each metal can vary widely depending on the source of the particles.  Nickel (Ni) is frequently a 
major component of ROFA (149;150) and needs to be considered as a factor in the biological 
effects of PM.  Ni exposure in the lower airways is associated with immunological sensitization, 
epithelial dysplasia, asthma, and fibrosis (151;152).  Moreover, Ni is a well-established 
respiratory carcinogen in man (153-155) and appears to synergistically interact with other metals 
to amplify their toxic effects (75;156).  Animal studies show that exposure of mice to nickel 
subsulfide by inhalation resulted in inflammation, hyperplasia, and fibrosis in the lung and 
inflammation and atrophy of the olfactory epithelium in the nose (157).  More recent studies 
demonstrate that it is water-soluble nickel that is responsible for much of the pulmonary injury 
caused by ROFA (158).  At the cellular level, Ni modulates gene expression by stimulating 
multiple signaling cascades in airway epithelium including, hypoxia-inducible factor (HIF-1α), 
AP-1, and other novel pathways (142;159;160).  We previously reported that both ROFA and 
nickel sulfate could interact with microbial stimuli during in vitro mycoplasma infection to 
markedly amplify the release of the immunomodulatory cytokine, IL-6, by human lung 
fibroblasts.  The specific mechanisms responsible for this interaction remain to be identified and 
it is not clear if both stimuli are required simultaneously or if one stimulus can modulate the 
subsequent responsiveness to the other.  Since other heavy metals did not show the same effects 
as nickel sulfate when co-exposed with MALP-2, I hypothesize that nickel sulfate plays the 
major role by facilitating the action of MALP-2 in producing IL-6 in HLF. 
 
Mitogen-and stress-activated protein kinase (MAPK / SAPK) pathways are among the best 
studied signaling routes that play crucial roles in many aspects of inflammatory responses.  
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 Several MAPK pathways (p38, ERK1/2 (p42/p44) and c-Jun N-terminal protein kinase (JNK)) in 
murine macrophages are activated by soluble factors derived from M. fermentans such as 
macrophage-activating lipopeptide 2 (MALP-2) and were required for induction of AP-1 and 
NF-κB activity , as well as cytokine secretion in these cells (49).  Similarly, several of the metals 
present in ROFA stimulate MAPK activation by acting as potent inhibitors of protein tyrosine 
phosphatase activity (161;162).  In line with its role as a contact sensitizer, Ni-induced activation 
of dendritic cells is associated with activation of the p38 MAPK module (163-165).  Hence, I 
sought to further define the molecular signaling mechanisms responsible to the synergistic 
interactions between Ni and microbial stimuli and hypothesized that specific MAPK pathways 
might play roles in the amplified production of IL-6 by HLF exposed to NiSO4 and MALP-2.   
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 3.2.3. Material and Methods 
 
Materials 
Cell culture medium and fetal bovine serum (FBS) were from Invitrogen (Gaithersburg, MD).  
Tissue culture plasticware was from Falcon (Becton-Dickinson, Franklin Lakes, NJ) with the 
exception of 60 mm2 dishes from Costar (Corning, NY).  Calf thymus DNA, Hoechst 33258 and 
nickel sulfate were from Sigma (St. Louis, MO).  Low endotoxin bovine serum albumin (BSA) 
was from Intergen (Purchase, NY) and M. fermentans-derived macrophage-activating 
lipopeptide-2 (MALP-2) was from Alexis Biochemicals (San Diego, CA).  Bradford protein 
assay reagent was from Bio-Rad (Hercules, CA).  Murine leukemia reverse transcriptase, RNAse 
inhibitor, deoxynucleotides, oligo-dT and Taq DNA polymerase were from Promega (Madison, 
WI).  MAP kinase inhibitors SB203580, PD98059 and SP600125 were from Alexis 
Biochemicals.  IL-6 specific enzyme-linked immunosorbent assay (ELISA) kits were from R&D 
Systems (Minneapolis, MN). 
 
Cell culture 
Human lung fibroblasts (HLF) were isolated and maintained as previously described (98) in 
accordance with a protocol approved by University of Pittsburgh Institutional Review Board.  
The individual cell lines were recovered from early passage frozen stocks and six different cell 
lines were pooled together and used for experiments over no more than eight additional 
subcultures.  Cells were maintained in Minimal Essential Medium (MEM) supplemented with 
FBS (10 %, final concentration), glutamine (2 mM), penicillin (100 U / ml), streptomycin (100 
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 µg / ml) in a humidified incubator at 37 °C with 5 % CO2 / 95 % air.  All cultures were negative 
for mycoplasma as determined by fluorescent microscopy using Hoechst 33258 dye (123). 
 
mRNA Measurement 
Conditioned media were collected for ELISA to verify the synergistic interaction before mRNA 
analysis.  Total cellular RNA was harvested using RNeasy Mini Kit (Cat. No. 74104 from 
Qiagen, Valencia, CA) according to the manufacturer's instructions.  Reverse transcription-
polymerase chain reaction (RT-PCR) was performed with 1 µg of the resulting RNA, as 
described previously (166).  Specific primer pairs for IL-6 (forward 5'-
GCCCAGCTATGAACTCCTTCTC; reverse 5'-GACTTGTCATGTCCTGCAGCC), ß-actin 
(forward 5'-GGGACCTGACCGACTACCTC; reverse 5'-GGGCGATGATCTTGATCTTC), 
were used to amplify the specific cDNAs.  PCR reactions were carried out for 20 s at 95 °C, 30 s 
at 55 °C, and 40 s at 72 °C for 17 cycles for ß-actin and 24 cycles for IL-6.  PCR products were 
either detected on 2 % agarose gels stained with ethidium bromide or quantified in real-time 
fashion during the PCR amplification using the double-strand DNA fluorescent dye PicoGreen at 
430 nm emission and 525 nm excitation.  IL-6 mRNA expression were normalized to the 
housekeeping gene ß-actin by determining the ratio of the IL-6 fluorescent signals to those for ß-
actin. 
 
Western Blot Analysis 
 Cells were washed twice with cold 1x phosphate-buffered saline (PBS) and collected with 40 
µl/dish RIPA buffer (150 mM NaCl, 1 % NP-40, 0.25 % sodium deoxycholate, 1 mM EDTA, 50 
mM Tris, pH7.4) supplemented with leupeptin, aprotinin, pepstatin (1 µg / ml each), 1 mM 
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 phenymethylsulfonyl fluoride, 1 mM sodium fluoride and 1 mM sodium orthovanadate .  Lysates 
were rocked on ice for 15 min and clarified by centrifugation at 12,000 x g for 7 min.  The 
obtained supernatants were aliquoted, flash frozen in EtOH / dry ice and stored at -80 oC.  
Samples were analyzed for protein according to Bradford assay (Bio-rad, Hercules, CA).  Total 
cell proteins were prepared by using RIPA buffer, 0.1 M DTT and 6X LB (0.35 M Tris-HCl (pH 
6.8 @ 25 oC), 0.35 M SDS, 30 % glycerol, 0.175 mM bromphenol blue).  Samples were heated 
at 95 oC for 3 minutes and 60 µg of protein were loaded onto 12 % SDS polyacrylamide gels.  
After separation, proteins were transferred to PVDF membrane (NEN life Sciences, Boston, 
MA).  Ponceau S Staining was applied to verify that equal amounts of protein per lane were 
transferred to the blot.  Immunoblots were developed using the MAPK pathway 
immunodetection kits (Cell Signaling technology, Beverly, MA).  Briefly, PVDF membrane with 
transferred proteins was washed with 25 ml of 1 x Tris-buffered saline (TBS) and blocked for 1 
hour at room temperature with 25 ml of Blocking Buffer (5 % w / v nonfat dry milk in 1x TBS 
supplemented with 0.1 % Tween-20).  Membrane was washed 3 times with 15 ml of 1x TBST 
for 5 min each after blocking and incubated overnight at 4 oC with 1:1000 dilution of primary 
antibody in 10 ml primary antibody in Blocking Buffer.  After incubation, membrane was 
washed for 3 times with 15 ml 1 x TBST and incubated with 1:2000 dilution of anti-rabbit IgG 
and 1:1000 dilution of anti-biotin for one hour at room temperature in 10 ml Blocking Buffer.  
Membrane was washed 3 times with 15 ml 1 x TBST for 5 min each and incubated for about 1 
min with 10 ml of Lumiglo and peroxide reagents solution and chemiluminescent image was 
then captured using EPi chemi II darkroom (UVP Inc., Upland, California).  Membranes were 
probed sequentially with phospho-specific MAPK primary antibodies to measure the activated 
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 form of each isoform, followed by an antibody detecting total (phosphorylated and 
unphosphorylated) MAPK protein.  Data were analyzed by Labwork software. 
 
Statistical analysis 
Data presented are expressed as mean ± SEM collected from at least three individual 
experiments.  Comparisons were made using a one-way ANOVA followed by appropriate group 
comparisons such as Dunnett's multiple comparison to control or Bonferonni's correction for 
multiple t-tests.  Statistical analyses were performed using GraphPad PRISMTM, version 3.0 
(GraphPadTM Software, San Diego, CA), and differences were considered significant at p < 0.05. 
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 3.2.4. Results 
 
NiSO4 and MALP-2 Co-exposure Synergistically Induces IL-6 mRNA and Protein 
Production. 
 
My previous study (166) observing the synergistic interactions between chemical (ROFA, 
NiSO4) and microbial stimulation was restricted to times following 24 and 48 hrs of concurrent 
exposure.  In order to more carefully delineate the time course and correlate the temporal 
relationship between changes in IL-6 mRNA gene and protein expression, IL-6 mRNA in cells 
and IL-6 protein in media were both measured at varying times after simultaneous exposure to 
NiSO4 (200 µM) and MALP-2 (600 pg / ml).  Cells were seeded into 6 well plates at 4-6 x 105 
cells / 4 mls / well and incubated for 2 days.  Confluent cells were washed once with 1 x PBS 
and changed to fresh serum-free MEM with 0.1% BSA. Cells were then exposed to NiSO4 
(200 µM) or MALP-2 (600 pg / ml) or both for a varying periods of time.  Conditioned media 
were collected for ELISA and total cellular RNA was harvested using RNeasy Mini Kit.  Figure 
7A shows a typical gel of IL-6 and β-actin RT-PCR products obtained from HLF.  IL-6 mRNA 
was barely detectable in any samples in the absence of any stimulus and both Ni and MALP-2 
alone appeared to produce a measurable response of approximately equivalent magnitude.  The 
combination of Ni and MALP-2 together, however, produced a robust signal that was much 
greater than either single stimulus alone at all of the selected time points.  IL-6 mRNA levels 
were quantified using real-time RT-PCR and normalized to the expression of β-actin.  Figure 7B 
shows that the Ni / MALP-2 combination produced an early, approximately 12-fold increase in 
IL-6 mRNA that was substantially greater than the 3 – 4 fold increases seen with MALP-2 or Ni 
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 alone at this same time.  This early increase was transient with a consistent fall in mRNA at the 4 
hr time point, however, as time progressed between 4 and 30 hrs, a prolonged and persistent 
accumulation of IL-6 transcripts was observed only in the cells exposed to Ni / MALP-2 
combination while IL-6 mRNA in response to either agent alone remained unchanged.  When 
IL-6 protein in conditioned media was measured by ELISA (Figure 7C) similar levels of IL-6 
accumulated over time in response to Ni or MALP-2 alone.  While significantly more IL-6 was 
measured at all time points for the combined stimulation, the most robust enhancement of IL-6 
release offered by combined exposure occurred only after 8 hrs of stimulation and correlated 
with late prolonged phase of mRNA accumulation seen in Figure 7B. 
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Figure 7:  NiSO4 and MALP-2 co-exposure induces synergistic increases in IL-6 mRNA and protein.    
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Nickel sulfate Pre-treatment Facilitates MALP-2 Effects on IL-6 Production. 
 
The synergistic stimulation of IL-6 expression by nickel and MALP-2 may require simultaneous 
presence of both stimulants.  Alternatively, the delay between exposure and manifestations of 
maximal synergy suggests that one stimulus may condition cells to respond to subsequent 
challenge with the other stimulus.  To test if single exposure to either agent could modulate the 
subsequent response to the other we pretreated cells with either NiSO4 or MALP-2 alone for 24 
hours.  A control group of cells was incubated in serum-free MEM (w / 0.1 % BSA) with no 
added stimuli.  Media was then replaced with fresh serum-free media with cells from each 
pretreatment group receiving NiSO4, MALP-2, NiSO4 / MALP-2 combined or no addition.  Cells 
were allowed to condition the media for 24 hrs at which time it was collected and assayed for IL-
6 content by ELISA.  Figure 8 shows that nickel sulfate-pretreated cells produced a significantly 
larger amount of IL-6 in response to subsequent stimulation with MALP-2 alone or NiSO4 / 
MALP-2 combined than did non-pretreated control cells.  In these Ni-pretreated cells, secondary 
stimulation with simultaneous NiSO4 and MALP-2 produced a greater response compared to 
MALP-2 alone.  In contrast, pretreatment with MALP-2 produced no significant difference in 
IL-6 production in response to any subsequent challenge stimulus compared to control non-
pretreated cells.  These data suggest that exposure to NiSO4 can enhance the ultimate response of 
HLF to the microbial product, MALP-2. 
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Figure 8:  Nickel sulfate pretreatment facilitates MALP-2 –induced IL-6 production in HLFs.  
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Nickel sulfate Induces ERK and JNK Phosphorylation 
 
The next step was to define mechanisms by which NiSO4 potentiates MALP-2 effects on IL-6 
production.  Mitogen activated protein kinases (MAPK) are known to play a crucial role in many 
aspects of immune-mediated and inflammatory responses.  Ni has been demonstrated to activate 
MAPK pathway activation in human dendritic cells (163;164), whereas synthetic MALP-2 also 
induces cytokine secretion in macrophages via activation of MAP kinases, p38, ERK1/2 (p42 / 
p44) and c-Jun N-terminal protein kinase (JNK) (167).  My biphasic pre-treatment/treatment 
protocol allowed temporal separation of the signaling events used by each stimulus.  Therefore, 
we could specifically address the role of MAPK in response of each stimulus.  To test if Ni-
mediated facilitation of MALP-2 depended on Ni-induced activation of specific MAPK, the time 
course of MAPK activation was followed by monitoring the phosphorylation status of the 
specific MAPK isoforms (ERK1/2, p38, JNK) after exposure to 200 µM NiSO4 alone.  Western 
blot analysis using antibodies specific for the phosphorylated forms of each MAPK subtype 
show that exposure to nickel sulfate alone leads to phosphorylation of ERK1/2 and JNK in HLF.  
ERK1/2 activation was very rapid with peak signal observed at 10 minutes and then diminishing 
to control levels by 2 hrs.  The pattern for the 46 kD form of JNK appeared similar to that seen 
with ERK1/2 with the exception that levels of phospho-JNK-46 appeared elevated relative to 
control at even longer times.  For the 54 kD from of JNK the time course of activation was 
somewhat slower with peak phosphorylation observed at 1 hr post-stimulation.  The levels of 
phosphorylated p38 remained very low or undetectable at all times following Ni exposure.  
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Figure 9:  Nickel sulfate induces ERK1/2 and JNK phosphorylation while phosphorylation level of p38 is 
undetectable. 
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Inhibition of MAP Kinase MEK/ERK1/2 or p38 Reduce the Ability of NiSO4 to Potentiate 
MALP-2-induced IL-6 Production 
 
I next tested whether the enhanced MALP-2 response observed after Ni-pretreatment was 
dependent upon the ability of Ni to activate specific MAPK pathways.  To this end I used three 
specific MAPK inhibitors:  PD-98059, a synthetic compound that specifically inhibits the ERK-
activating MAPK kinase MEK-1 (168;169), SB203580, a p38 pathway inhibitor (170;171), and 
SP600125, a c-Jun N-terminal protein kinase (JNK) inhibitor (172;173).  Since the synergistic 
interactions between Ni and MALP-2 can be reproduced with sequential treatment of Ni 
followed by MALP-2, experiments were set up to examine involvement of MAP kinases at both 
the Ni-pretreatment phase, as well as the MALP-2 challenge phase.  In one set of experiments, 
HLF were first pretreated with NiSO4 for 24 hours in the presence or absence of each MAPK 
inhibitor followed by challenge with MALP-2 in the absence of the inhibitor for an additional 24 
hours.  In another set of experiments, I omitted the MAPK inhibitors during the pretreatment 
phase with NiSO4, but included them during the second phase with MALP-2.  It should be noted 
that cells were washed and replenished with fresh serum-free medium prior to the initiation of 
the MALP-2 challenge so that the IL-6 response represents the amount released only during the 
24 hr MALP-2 treatment.  Figure 10 shows the ability of various MAPK inhibitors to modulate 
MALP-2-induced IL-6 release when applied during the Ni pretreatment phase or the MALP-2 
challenge itself.  I found application of PD 98059 or SB 203580 during the NiSO4 pre-treatment 
phase alone decreases the subsequent MALP-2 induction of IL-6.  This effect was specific for Ni 
pretreatment since application of the same concentrations of MAPK inhibitors (20µM) during 
the MALP-2 treatment phase was without effect.  The JNK inhibitor SP600125 failed to 
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 attenuate IL-6 release when applied at either time.  These results suggest that Ni-induced 
activation of specific MAPK isoforms, like ERK1/2 and perhaps p38, are important determinants 
in the Ni-dependent modulation of cytokine release following MALP-2 exposure.   
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Figure 10:  Blocked of MAP Kinase MEK/ERK1/2 and p38 pathways reduce the ability of NiSO4 to enhance 
MALP-2-induced IL-6 production.     
 
62 
  
 
MEK/ERK1/2 is Involved in the Synergistic Upregulation of IL-6 Protein and mRNA 
Expression during Concurrent MALP-2 and Nickel Sulfate Coexposure. 
 
I next wanted to determine how various MAPK inhibitors would impact the synergistic 
interactions between Ni and MALP-2 when the two stimuli were applied simultaneously and 
whether the pattern of inhibition was distinct from the ability to modulate the response to either 
single stimulus alone.  In addition, since the results in Figure 11 show less than complete 
inhibition for any one single MAPK antagonist, the effects of various combinations of MAPK 
inhibitors were also determined.  For this, HLF were treated with MAPK inhibitors (20 µM), 
alone or in combinations for one hr prior to the addition of NiSO4 (200 µM), MALP-2 (600 pg / 
ml), or Ni + MALP-2.  Incubations were continued in the presence of MAPK inhibitors for 24 
hrs at which time medium was collected and analyzed for IL-6 by ELISA.  Figure 11A shows 
that when the MAPK inhibitors were applied as single agents during combined Ni / MALP-2 
exposure, only PD98059 produced significant inhibition (33 %) whereas the p38 and JNK 
inhibitors did not.  In addition, no further enhancement of PD98059 was observed when it was 
applied in combination with SB203580.  With the exception of SP + PD combination, which 
may reflect a slight stimulatory effect of JNK inhibitor (see Figure 11B), PD98059 treatment 
always produced a significant attenuation of the MALP-2 + Ni response either alone or in 
combination with other antagonists.  In addition, I also observed that the simultaneous presence 
of the p38 and JNK inhibitors significantly inhibited IL-6 release in response to MALP-2 + Ni, 
although either agent alone was without effect.  Figure 11B and 11C show the responses to Ni 
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 and MALP-2 alone, respectively.  Note the differences in scale of the y-axes compared to Figure 
11A, which reflects the synergistic interaction when Ni and MALP-2 are combined.  In contrast 
to that seen with Ni + MALP-2, inhibition of the MEK/ERK1/2 pathway did not attenuate IL-6 
release to either stimulus alone.  None of the combinations of MAPK inhibitors affected the 
response to Ni alone with the exception of SP600125, which produced a slight but significant 
enhancement of IL-6 release.  The response to MALP-2 alone was reduced in the simultaneous 
presence of all three MAPK inhibitors, however most likely reflects the effects of combined 
SB203580 and SP600125 which was similar in magnitude to effect of SB + SP + PD, but 
narrowly failed to meet statistical significance.  Therefore, it appears that inhibition of ERK1/2 
pathway of MAPK can attenuate the response to the combination of Ni and MALP-2 and that 
this effect is unique to the combined stimuli since similar patterns of inhibition were not 
observed when PD 98059 was applied with either Ni or MALP-2 alone.  I also observed that 
joint inhibition of p38 and JNK could attenuate the response to MALP-2 + Ni response, whereas 
inhibition of either one alone was insufficient.  The effect was not specific for the combined 
stimuli since a similar pattern was observed in response to MALP-2 alone. 
 
The role of ERK1/2 was further substantiated in an experiment that separately assessed IL-6 
gene expression at the mRNA level.  In this experiment HLFs were stimulated Ni + MALP-2 in 
the presence or absence of PD 98059, SB 203580, and SP 600125 (20µM each).  Since the time 
course of mRNA accumulation (see Fig. 7B) revealed a biphasic response in IL-6 transcript 
accumulation, cells were harvested and RNA prepared at both 2 and 24 hrs post-treatment to 
correspond to the early and late mRNA response.  Figure 12 shows the amount of IL-6 mRNA 
normalized to β-actin present in HLF at 2 and 24 hrs after stimulation.  In the absence of any 
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 MAPK inhibitor the amount of mRNA was about three-fold higher at the 24 hr time point 
compared to 2 hrs after stimulation.  The accumulation of mRNA at the early 2 hr time point was 
essentially unchanged by any of the MAPK inhibitors.  In contrast, the ERK1/2 pathway 
inhibitor produced a significant reduction in the mRNA response observed at 24 hrs, whereas the 
remaining 2 inhibitors, SP 600125 and SB 203580, were without effect.  Taken together, my data 
indicate that MEK-ERK1/2 MAP kinase pathway plays an important role in mediating the 
synergy between NiSO4 and MALP-2 in augmenting IL-6 gene expression. 
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Figure 11:  MAP kinase MEK/ERK1/2 pathway inhibitor PD98059 partially inhibits the synergy between 
MALP-2 and nickel sulfate in IL-6 production by HLF.   
66 
 Control PD 98059 SB 203580 SP 600125
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
24 hr
2 hr
Inhibitor Treatment
IL
-6
/ β-
ac
tin
 m
RN
A 
(a
rb
itr
ar
y 
un
its
) *
 
Figure 12:  MAP kinase MEK/ERK pathway inhibitor PD98059 partially inhibits the synergy between 
MALP-2 and nickel sulfate in IL-6 mRNA production by HLF. 
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 3.2.5. Discussion 
This study is the first to explore the mechanisms of the unique synergistic interaction between 
NiSO4 and MALP-2 in human lung fibroblasts.  MAP kinase pathways are important targets for 
ROFA-induced cellular and biochemical responses, while the mechanism by which ROFA 
activates these signaling pathways is not known.  One mechanism of ROFA-induced MAP 
kinase activation could be the induction of an oxidative stress due to the high content of 
bioavailable metals, predominantly vanadium and nickel.  In vivo study shows that ROFA induced 
activation of pulmonary ERK1/2, and the ERK1/2 activation was inhibited at the cellular, 
biochemical, and functional levels by dimethylthiourea (DMTU), an oxygen radical scavenger, 
which supports the role for oxidative stress in this response (148).  These results are consistent 
with a number of in vitro studies that have demonstrated the ability of oxidative stress generated 
by ROFA-associated metals to induce MAP kinases (174;175).  Another possible mechanism for 
ROFA-induced activation of pulmonary MAP kinases could be by the inhibition of tyrosine 
phosphatase activity as shown by Samet et al. using human bronchial epithelial cells (143;176).  In 
vivo studies show that there was a pronounced inflammatory response to ROFA instillation and a 
marked increase in levels of P-Tyr and P-MAPKs present within the alveolar epithelium and in 
the inflammatory cells, while the airway epithelium showed a prolonged increase in the 
expression of P-ERK1/2 (161).   Nickel, one of the main metal component in ROFA, activates 
MAP kinase signaling cascades in different type of cells (159;164;165), but little is known about 
nickel’s effect on MAP kinase in human lung fibroblasts.  This study is the first to examine the 
possibility of nickel-induced MAPK activation in HLF.  Acute exposure to nickel sulfate induced 
a rapid activation of two distinct MAPKs, ERK1/2 and JNK (Fig. 9), while blocking MEK / 
68 
 ERK1/2, not JNK pathway can partially abolish nickel sulfate’s facilitation effects on MALP-2 
(Fig.10) in human lung fibroblasts.  
 
The hypothesis that nickel sulfate potentiates MALP-2 effects on IL-6 production by activating 
MER / ERK1/2 pathway was verified in another experiment when MAP kinase inhibitors were 
given at different phases to examine the involvement of MAP kinase during both the Ni-
pretreatment phase, as well as the MALP-2 challenge phase.  The result of this experiment gives 
rise to two other issues.  First, although nickel sulfate cause JNK phosphorylation, it is not 
responsible for its potentiating effects on MALP-2 since the corresponding JNK specific 
inhibitor failed to decrease the IL-6 production at either phase of the study.  Secondly, although 
the levels of phosphorylated p38 remained very low or undetectable at all times following Ni 
exposure, the data from Figure 10 shows that blocking p38 by SB203580 can partially diminish 
nickel sulfate’s effects on assisting MALP-2 on IL-6 protein release.  Recently study by 
Numazawa et al. suggested that a steady-state level of the p38 MAP kinase activity is required 
for the nuclear translocation of ERK1/2 (177).  Their study also strongly suggests that the p38 
MAP kinase activity participates in ERK nuclear translocation and thereby positively regulates 
ERK-mediated signal transduction at multiple steps (177).  SB 203580 has been widely used to 
specifically shut down the p38 MAP kinase-dependent pathway, its inhibition effects on IL-6 
release in my study is probably due to the impaired ERK –mediated signal transduction caused 
by inactivation of basal p38 MAP kinase activity.  However, there could be other possibilities 
such as the cross-talk between MAPK signaling pathways, involvement of other upstream 
kinases in addition to MAP kinase or even other signaling pathways activated in the interactive 
effects between nickel and MALP-2 since the inhibitor experiments cannot fully block the 
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 effects of nickel sulfate or the combination effects on IL-6 production.  My further studies 
suggest that even though there may be some cross-talk or uncertainty about the whole MAPK 
pathway effects on nickel sulfate and MALP-2 exposure, blocking MEK / ERK1/2 signaling 
pathway still can partially diminish the synergistic IL-6 mRNA and protein production by the 
combination of NiSO4 and MALP-2 (Fig 11, 12).  Another important issue is the relationship 
between MALP-2 and MAPK activation. Studies show that the inhibition of MEK / ERK1/2 by 
PD98059 treatment partially inhibited, in a dose-dependent manner, cytokine production by 
RAW 265.7 in response to MALP-2 (49).  In addition, ERK1/2 and p38 pathway inhibitors, 
respectively, partially or completely inhibited cytokine production in the human cell line THP-1 
stimulated with sMALP-2 or LPS (47).  Little is known about MALP-2 and MAPK activation in 
human lung fibroblasts.  My study shows that Nickel-induced MAPK activation leads to further 
MALP-2 related IL-6 production in HLF.  MEK / ERK1/2 pathway was confirmed to play a role 
in the synergistic interaction between nickel sulfate and MALP-2 in IL-6 production, but p38 
may also be involved.  p38 inhibitor SB 203580 partially inhibited IL-6 production in the pre-
treatment model, while it failed to inhibit the interaction of nickel sulfate and MALP-2 when 
both were given at the same time.  This suggested that phosphorylation of MAPK pathways in 
different orders would affect the synergistic IL-6 production in HLF by the combination of Ni 
and MALP-2.   
 
Another important issue about the mechanisms of nickel and MALP-2 inducing IL-6 production 
in human lung fibroblasts that has not been touched in this study is the IL-6 gene stability.  
Nickel sulfate and MALP-2 effects on IL-6 gene stability is another direction that needs to be 
revealed to better study the mechanisms of this unique effects. 
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  3.3. Chapter 3 
Transcriptional regulation of IL-6 gene by MALP-2 and NiSO4 in Human Lung Fibroblasts
 
                                                        
 
 3.3.1. Introduction 
IL-6 is a multi-functional cytokine that plays a central role in host defense mechanisms.  It is 
produced by many cell types and influences function of immune and other types of cells.  IL-6 
elicits major changes in the biochemical, physiological and immunological status of the host (e.g. 
the "acute phase" plasma protein response).  IL-6 enhances plasma protein gene expression not 
only in hepatocytes but also in monocytes, fibroblasts and lymphocytes (178).  In addition, IL-6 
is believed to play a role in the pathogenesis of pulmonary fibrosis (179;180), rheumatoid 
arthritis (181), systemic lupus erythematosus (182;183) and other immune-mediated diseases 
(184-186).   
 
The expression of IL-6 is controlled at both transcriptional and post-transcriptional levels.  While 
less is known about the mechanism for post-transcriptional regulation, several studies have 
identified sequence elements in IL-6 promoter that mediate its regulated expression by 
physiological stimuli and environmental insults.  The human IL-6 promoter contains multiple 
regulatory elements including NF-κB (-75 / -63), NF-IL6 (-158 / -145) and AP-1 (-283 / -277).  
AP-1 activity is induced by a variety of physiological stimuli and environmental insults such as 
growth factors, cytokines, neurotransmitters, polypeptide hormones, cell–matrix interactions, 
bacterial and viral infections and air pollution particles.  These stimuli activate mitogen activated 
protein kinase (MAPK) cascades that enhance AP-1 activity through the phosphorylation of 
distinct substrates (187).  In turn, AP-1 regulates a wide range of cellular processes, including 
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 cell proliferation, death, survival and differentiation.  NF-κB is another crucial transcriptional 
factor that regulates IL-6 gene expression.  NF-κB belongs to the Rel family of transcription 
factors that form homo- or heterodimers through the Rel homology domain (188;189).  In most 
cells, NF-κB is present in the cytoplasm bound to a member of the IκB family of inhibitors 
(190;191).  Upon activation of the cells by cytokines, such as TNF-α and IL-1, viruses, bacteria, 
or mitogens, IκB is phosphorylated and then rapidly degraded allowing the translocation of NF-
κB to the nucleus where it binds to specific DNA binding sites.  Like NF-κB, NF-IL6 is 
ubiquitously expressed but functionally regulated at translational and post-translational levels.  
NF-IL6 is a member of a C/EBP family. It not only regulates the expression of IL-6, but also 
induces various acute phase proteins (192).  Several lines of evidence suggest that members of 
the NF-κB, C/EBP, and AP-1 transcription factor families may work in concert to regulate the 
IL-6 promoter in a cell-type- or inducer-specific fashion (193-196).  Indeed, a physical and 
functional interplay among all three classes of proteins has been widely demonstrated (197;198).  
It has been shown that air pollution particles induce activation of NF-κB and other transcription 
factors in lung epithelial cells (199).  Studies also show that MALP-2 induce cytokine production 
via NF-κB and AP-1 activation (200;201).  In the previous studies, I have demonstrated that 
NiSO4 and MALP-2 synergistically induce pro-inflammatory cytokine IL-6 release by human 
lung fibroblasts.  I also found that extracellular signal-regulated kinase (ERK1/2) plays a role in 
this synergistic interaction between MALP-2 and NiSO4.  These findings raise the possibility that 
MALP-2 and nickel sulfate synergistically increase IL-6 gene transcription by activating 
different transcriptional factors.  I tested this possibility using luciferase-based reporter gene 
constructs containing various forms of the human IL-6 promoter.  Three forms of wildtype 
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 human IL-6 promoter of progressing increasing length along with a series of mutant promoters 
containing alterations in specific transcription factor binding sites were utilized for these studies. 
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 3.3.2. Material and Methods 
Materials 
QIAEX II Gel extraction kit (Cat. No. 20021), High purity midiprep (Cat. No. 12143) and 
QIAprep spin miniprep kit (Cat. No. 27104) were from Qiagen (Valencia, CA).  TOPO TA 
cloning kit (Cat. No. K4530-20) and LIPOFECTAMINE PLUS Reagent were from Invitrogen 
(Carlsbad, CA).  pGL3-basic luciferase vector (Cat. No. E1751), the Dual-Luciferase™ Reporter 
Assay System (Cat. No. E1960) and Passive Lysis 5 X Buffer (Cat. No. E1941) were from 
Promega (San Luis Obispo, CA).  Forward (5’-CATAGACGGATCACAGTGCA-3’) and 
reverse primer (5’-TGTGGA GAAGGAGTTCATAGC-3’) was purchased from Integrated DNA 
Technologies, Inc. (Coralville, IA).  T4 DNA ligase (Cat. No.10481220001) was from Roche 
Applied Science (Indianapolis, IN).   XL10-Gold® Ultracompetent cells (Cat. No. 200314) and 
QuikChange® XL Site-Directed Mutagenesis Kit were from Stratagene (La Jolla, CA).   
 
Cell culture 
Human lung fibroblasts (HLF) were maintained in Minimal Essential Medium (MEM) 
supplemented with FBS (10 %, final concentration), glutamine (2 mM), penicillin (100 U / ml), 
streptomycin (100 µg / ml) in a humidified incubator at 37 °C with 5 % CO2 / 95 % air.  All 
cultures were negative for mycoplasma as determined by fluorescent microscopy using Hoechst 
33258 dye (123). 
 
Luciferase reporter gene assays 
Human lung fibroblasts were plated onto 12-well plates (2 x 105 cells / well) in MEM containing 
10 % FBS.  Twenty-four hours later, the cells were washed with 1x PBS and fed 400 µl fresh 
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 Dulbecco's modified eagle's medium (DMEM) without antibiotics and serum.  Cells were 
transfected using Lipofectamine-Plus with 0.3 µg IL-6 or mutant promoter reporter construct and 
0.1 µg pRL-tk containing Herpes simplex virus thymidine kinase promoter / well for 3 h 
according to the manufacturer’s protocol.  After the incubation, the medium was replaced with 
MEM medium containing 10 % FBS and incubated overnight.  Cells were washed again with 1x 
PBS and changed to serum-free MEM medium containing 0.1 % BSA before being exposed to 
NiSO4 (200 µM) and / or MALP-2 (600 pg / ml).  IL-1β (10 ng / ml) was used as a positive 
control.  After the 24 hrs incubation, supernatants were collected and stored for ELISA and cells 
were harvested with 150 µl passive lysis buffer / well and collect into microcentrifuge tubes.  
After centrifuging at 14000 rpm for 10 min, supernatants were collected and dual luciferase 
activities were determined according to the manufacturer's protocol.  
 
Statistical analysis 
Data presented are expressed as mean ± SEM collected from at least three individual 
experiments.  Comparisons were made using a one-way ANOVA followed by appropriate group 
comparisons such as Bonferonni's correction for multiple t-tests.  Statistical analyses were 
performed using GraphPad PRISMTM, version 3.0 (GraphPadTM Software, San Diego, CA), and 
differences were considered significant at p < 0.05. 
  
3.3.3. Rationale  
Making human IL-6 promoter-luciferase reporter construct (see Fig. 13) 
An approximate 1.7 kb DNA fragment downstream from the IL-6 protein coding sequence was 
amplified from HEK293 genomic DNA by polymerase chain reaction (PCR) with primers (5’-
75 
 CAT AGA CGG ATC ACA GTG CA-3’(+13-+32) and 5’-TGT GGA GAA GGA GTT CAT 
AGC-3’ (-1744- -1764).  The PCR product was extracted by using QIAEX II Gel extraction kit 
and cloned into a pCR2.1-TOPO TA vector.  Multiple clones were selected and grown by 6 
hours incubation in LB broth, DNA from individual clones were extracted by QIAprep spin 
miniprep kit and digested by BamHI restriction enzyme for 30 minutes.  After digestion, clones 
with the appropriate orientation were detected by running 1% agarose gel and grown overnight. 
Clones and PGL3-Basic vector were digested with endonuclease enzymes and ligated using T4 
DNA ligase. Transformation was performed by using XL10-Gold Ultracompetent cells and DNA 
was purified by high purity midiprep.  Three IL-6 promoter-luciferase reporter constructs (-
1700IL-6luc, -860IL-6luc and -500IL-6luc) were then generated with pGL3-basic luciferase 
vector by using endogenous restriction enzyme sites on PCR-based methods.  The region -500-0 
contains the known AP-1, CREB (NF-IL6), and NF-κB sites (see Fig. 14 and 15).   
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 Primer IL6-F1: 5’-CAT AGA CGG ATC ACA GTG CA-3’
Primer IL6-R1: 5’-TGT GGA GAA GGA GTT CAT AGC-3’
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Figure 13:  Rationale of making IL-6 promoter with various lengths. 
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 -1683 TCGTCGAAAATACATAGACGGATCACAGTGCACGGCTGCGGATAGGGAGCAGTGGCTTCGTTTCATGCAGGAAAG
Forward primer 
AGCAGCTTTTATGTATCTGCCTAGTGTCACGTGCCGACGCCTATCCCTCGTCACCGAAGCAAAGTACGTCCTTTC
-1608 AGAACTTGGTTCAGGAGTGTCTACGTTGCTTAAGACAGGAGAGCACTAAAAATGAAACCATCCAGCCATCCTCCC
TCTTGAACCAAGTCCTCACAGATGCAACGAATTCTGTCCTCTCGTGATTTTTACTTTGGTAGGTCGGTAGGAGGG
-------------------------------------------------------------------------------------------------------
-333  ACTTCGTGCATGACTTCAGCTTTACTCTTTGTCAAGACATGCCAAAGTGCTGAGTCACTAATAAAAGAAAAAAAG
AP-1
TGAAGCACGTACTGAAGTCGAAATGAGAAACAGTTCTGTACGGTTTCACGACTCAGTGATTATTTTCTTTTTTTC
-258  AAAGTAAAGGAAGAGTGGTTCTGCTTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTTCCCCCTAGTT  
GRE
TTTCATTTCCTTCTCACCAAGACGAAGAATCGCGATCGGAGTTACTGCTGGATTCGACGTGAAAAGGGGGATCAA
-183  GTGTCTTGCGATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTTCCAATCAGCCCCACCCGCTCTGGCC
NF-IL6
CACAGAACGCTACGATTTCCTGCAGTGTAACGTGTTAGAATTATTCCAAAGGTTAGTCGGGGTGGGCGAGACCGG
-108  CCACCCTCACCCTCCAACAAAGATTTATCAAATGTGGGATTTTCCCATGAGTCTCAATATTAGAGTCTCAACCCC
NF-κB
GGTGGGAGTGGGAGGTTGTTTCTAAATAGTTTACACCCTAAAAGGGTACTCAGAGTTATAATCTCAGAGTTGGGG
-33  CAATAAATATAGGACTGGAGATGTCTGAGGCTCATTCTGCCCTCGAGCCCACCGGGAACGAAAGAGAAGCTCTAT
TATA element Major RNA start site
GTTATTTATATCCTGACCTCTACAGACTCCGAGTAAGACGGGAGCTCGGGTGGCCCTTGCTTTCTCTTCGAGATA
+43 CTCCCCTCCAGGAGCCCAGCTATGAACTCCTTCTCCACAAGTAAGTGCAGGAAATCCTTAGCCCTGGAACTGCCA   
GAGGGGAGGTCCTCGGGTCGATACTTGAGGAAGAGGTGTTCATTCACGTCCTTTAGGAATCGGGACCTTGACGGT
Reverse primer
Human IL-6 promoter
 
Figure 14:  IL-6 promoter gene sequence and important transcription factor sites 
 
 
Making human IL-6 promoter-luciferase reporter mutants (Fig. 15) 
 
IL-6 reporter gene constructs with a mutation in the NF-κB, the NF-IL6 or AP-1 site were 
generated by using QuikChange® XL Site-Directed Mutagenesis Kit according to the manual.  
The NF-κB site was disrupted by converting GGGATTTTCC to CTCATTTTCC, AP-1 site from 
TGAGTCAC to TGCAGCAC and NF-IL6 site from CACATTGCACAAT to 
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 CACACCGTTCAATCT.  Mutant IL-6 promoter-luciferase reporter constructs were generated 
within the context of the longest IL-6 promoter, -1700IL6luc. 
-333 ACTTCGTGCATGACTTCAGCTTTACTCTTTGTCAAGACATGCCAAAGTGCTGAGTCACTAATAAAAGAAAAAAAG
AP-1
-258 AAAGTAAAGGAAGAGTGGTTCTGCTTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTTCCCCCTAGTT  
GRE
-183 GTGTCTTGCGATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTTCCAATCAGCCCCACCCGCTCTGGCC
NF-IL6
-108 CCACCCTCACCCTCCAACAAAGATTTATCAAATGTGGGATTTTCCCATGAGTCTCAATATTAGAGTCTCAACCCC
NF-κB
-33 CAATAAATATAGGACTGGAGATGTCTGAGGCTCATTCTGCCCTCGAGCCCACCGGGAACGAAAGAGAAGCTCTAT
TATA element Major RNA start site
Major 
IL-6
Start
-5      +10
CA
-34   -21
TATA element
-73   -64
NF-κB
AP-1
-283 -276
-159   -147
-164   -158
CEBPβ/NF-IL6
CRE/TRE motif
-211   -197
GRE
+81
AP-1: 5’-TGA-GTC-AC-3’?5’-TGC-AGC-
CC-GTT-C
CTC-
AC-3’
NF-IL6: 5’-CAC-ATT-GCA-CAA-T-3’ ?5’-CAC-A AA-TCT-3’
NF-κB: 5’-GGG-ATT-TTC-C-3’? 5’ ATT-TTC-C- 3’
Site-mutation: 
 
Figure 15:  Rationale of making IL-6 promoter mutants. 
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 3.3.4. Results  
 
NiSO4 and MALP-2 Increase IL-6 Promoter Activity 
 
To study human IL-6 gene promoter activity, three luciferease reporter constructs each 
containing ~1.7-kb, 860-bp or 500-bp fragment of the human IL-6 5’flanking region were made 
(Fig. 16).  These constructs were transfected into human lung fibroblast cells and luciferase 
activities were compared following treatment of transfected cells with NiSO4 or MALP-2 (Fig. 
16).  Results showed that NiSO4 induced a very slight increase (Fig. 16) in IL-6 promoter 
activity compared to the basal level in untreated cells ranging from 26% with the shortest 
construct to 65% with the 1.7 kb promoter.  Only the response of the 1.7 kb fragment achieved 
statistical significant compare to control.  Similarly, MALP-2 induced minimal activation of IL-6 
promoter activity (Fig.16).  Similar to NiSO4-induced effect, MALP-2 caused a larger increase 
in IL-6 promoter activity with the two longer fragments.  Co-treatment with NiSO4 and MALP-2 
resulted in larger increase in IL-6 promoter activity compare to individual stimuli.  MALP-2 and 
NiSO4 co-exposure induced 1.9 ± 0.37, 2.3 ± 0.54 and 2.8 ± 0.65 fold increases in IL-6 promoter 
activity with 500-bp, 860-bp and 1700-bp constructs, respectively and were all significantly 
different from untreated control.  These relatively small effects were not due to the inability of 
transfected cells to respond to these stimuli, since simultaneous measurement of IL-6 release 
from the same preparations showed a dramatic synergistic enhancement of the cytokine 
production.  
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Figure 16:  NiSO4 and MALP-2 effects on IL-6 promoter activity.   
 
 
 
 
 
NF-κB Element is Essential for Optimal Basal IL-6 Promoter Activity 
 
To further investigate the importance of individual transcriptional factors in regulation of IL-6 
gene transcription in lung fibroblasts, I introduced mutations in the known NF-κB, AP-1 and NF-
IL6-binding sites in IL-6 promoter (Fig. 17).  I used the luciferase reporter with the longest 
fragment of IL-6 promoter (1.7 kb) for this purpose, because this construct responded the best to 
NiSO4 or MALP-2.  Compared to the wild-type IL-6 construct, basal IL-6 gene expression in the 
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 absence of any stimuli was dramatically decreased in NF-κB-mutant IL-6 promoter construct (87 
% decrease compared to wild type).  In contrast, much smaller reductions in the basal promoter 
activity were seen with AP-1 (44 %) or NF-IL6 (26 %) mutants.  Further study also showed that 
enhancement of IL-6 promoter activity by any of the exogenous stimuli was also dramatically 
decreased in NF-κB mutant IL-6 promoter construct. IL-1-induced IL-6 gene expression was 
totally abolished in this mutant IL-6 promoter (Fig. 18).  These findings suggest that NF-κB is 
essential for optimal IL-6 gene expression in human lung fibroblasts, however, it should be noted 
that a stimulatory effect of Ni could still be observed even in absence of a functional NF-κB cis-
element (Fig.17). 
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Figure 17:  IL-6 promoter mutants and basal level of IL-6 promoter activity.    
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NF-κB and NF-IL-6 are Involved in the Cooperative Interactions between MALP-2 and 
NiSO4. 
 
Next I tested whether the introduced mutations in transcription factor binding sites might 
influence IL-6 promoter activation in response to MALP-2 and NiSO4.  Using the 1.7 kb 
wildtype IL-6 promoter it was observed that the combination of Ni + MALP-2 approximately 
doubled the promoter activity (p < 0.05 relative to untreated control) and was of a similar 
magnitude to that seen with IL-1β (Fig 18A).  In contrast, the responses to Ni or MALP-2 alone 
were smaller and were not statistically significant when compared to control.  As discussed 
above, both basal and induced activity of the NF-κB mutant construct was substantially reduced 
(Fig. 18B).  Ni alone, as well as Ni + MALP-2, however, still appeared to be able to drive this 
minimally active promoter to a level about 2-fold above control levels.  The addition of MALP-2 
to Ni failed to augment the stimulatory effect observed with Ni alone.  While the overall 
magnitude of responses seen with the AP-1 mutant was reduced compared to the wildtype 
promoter, there remained a significant difference between the Ni alone and Ni + MALP-2 with 
greater induction by the latter (Fig.18C).  Therefore, the cooperative interactions between 
MALP-2 and Ni did not appear to fully require a functional AP-1 binding site.  In contrast, 
negation of NF-IL6 appeared to completely block any cooperation between Ni and MALP-2 
since the responses to Ni alone and Ni + MALP-2 were indistinguishable from each other and 
not statistically different from untreated control.  Therefore, it appears that the combination of Ni 
+ MALP-2 represents a more efficacious stimulus for driving the wildtype IL-6 promoter 
compared to either of the two stimuli applied separately.  Negation of either NF-κB or NF-IL-6, 
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 but not AP-1, binding sites eliminated any apparent functional cooperation between Ni and 
MALP-2.  Thus, the ability of MALP-2 and Ni to interact to amplify IL-6 release from HLF may 
involve cooperative interactions between specific transcription factors such as NF-κB and NF-
IL6. 
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Figure 18:  NiSO4 and MALP-2 effects on wildtype and mutant IL-6 promoters by human lung fibroblasts.    
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3.3.5. Discussion 
 
IL-6 production is positively or negatively regulated in various cell types by a variety of signals 
(202).  In fibroblasts and certain tumor cell lines, multiple cytokines, including IL-1, tumor 
necrosis factor (TNF), platelet-derived growth factor, and interferon-β enhance IL-6 production.  
In the promoter region of the IL-6 gene five known functional cis-regulatory elements have been 
described, namely cAMP-responsive element, activator protein-1 (AP-1), nuclear factor IL-6 
(NF-IL6), Sp1, and NF-κB binding sites (188).  Binding of specific nuclear transcription factors 
to such regulatory elements in the IL-6 gene promoter are known to play pivotal roles in the 
increased IL-6 production by cytokines and growth factors.  Among the transcription factors, NF-
κB is a heterodimer consisting of two proteins encoded by rel-family genes (203), NF-κB 
activation mediates critical cellular responses that control gene expression and programmed cell 
death (204).  Although both NF-κB and additional transcription factors such as AP-1 and NF-
IL6/CEBP, are required to maximally induce IL-6 gene transcription, the contribution of the κB 
regulatory element to the transcriptional activation of the IL-6 gene appears most prominent 
(205-209).  For example, NF-κB was found to be the most important for the transcriptional 
regulation of the IL-6 gene by IL-1 and TNF-α (210;211).  Likewise, in vivo targeting of the p50 
(NFKB1) subunit resulted in reduced expression of the IL-6 gene (212).  Moreover, in human 
airway epithelial cells, activation of NF-κB is associated with the expression of interleukin-6 (IL-
6) in response to ROFA exposure (213).  Activation of NF-κB by nickel compounds was also 
found in mouse fibroblasts (3T3), human bronchoepithelial cells (BEAS-2B) and skin dendritic 
cell line (214;215).  In the present study, I examined the roles of NF-κB and other regulatory 
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 elements in the increased IL-6 production exerted by MALP-2 and NiSO4.   Using site-directed 
mutagenesis and reporter gene assays, I have shown that the NF-κB element located near the 
transcription start site of the human IL-6 gene is essential for its basal expression in human lung 
fibroblasts as well as its activation by IL-1 or MALP-2.  It is noteworthy, however, that 
significant activation could be measured in response to Ni suggesting the importance of other 
factors in mediating the effects of this metal on gene expression. 
 
NF-IL6 belongs to a member of the CCAAT/enhancer binding protein (C/EBP) family of 
transcription factors.  These proteins comprise of a class of DNA-binding proteins called basic 
leucine zipper proteins that includes C/EBPα, C/EBPß (NF-IL6), C/EBPγ, and C/EBPδ (NF-
IL6ß) (216). They are characterized by a leucine zipper domain and a DNA-binding basic region 
located in the C-terminus of the proteins. Members of the C/EBP family can associate through 
the leucine zipper domain to form homo- and heterodimers with each other and bind with similar 
affinity to various C/EBP-binding DNA sequences (217;218).  NF-IL6 was shown to bind to the 
regulatory regions of various acute-phase protein genes and several other cytokine genes such as 
TNF, IL-8 and G-CSF.  These observations indicate that NF-IL6 coordinates expression of not 
only the IL-6 gene but also other genes involved in acute-phase reaction, inflammation and 
hemopoiesis (219).  Thus, NF-IL6 may be a pleiotropic mediator of many inducible genes 
involved in acute, immune, and inflammatory responses, similarly to NF-κB.  Indeed, both NF-
IL6- and NF-κB-binding sites are present in many inducible genes such as IL-6, IL-8, and 
several acute-phase genes (220).  Transcription factors NF-IL6 and NF-κB synergistically 
activate transcription of the inflammatory cytokines such as IL-6 and IL-8 by a process that 
involve their direct physical interaction (221). My study shows that the disruption of an NF-IL6 
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 site only mildly affects the basal promoter activity.  But, this mutation blocked the NiSO4 plus 
MALP-2-induced activation of IL-6 promoter activity.  Hence, unlike NF-κB, NF-IL6 is not 
required for the basal IL-6 transcription in human lung fibroblast, whereas it mediates, in part, 
the MALP-2 and NiSO4 induced IL-6 gene expression and importantly, is required for any 
cooperative interaction between these two stimuli. 
 
AP-1 was one of the first mammalian transcription factors to be identified (222), but its 
physiological functions are still being resolved. AP-1 is not a single protein, but a mix of dimeric 
basic region-leucine zipper (bZIP) proteins that belong to the Jun (c-Jun, JunB, JunD), Fos (c-
Fos, FosB, Fra-1 and Fra2) (223), Maf (c-Maf, MafB, MafA, MafG/F/K and Nrl) and ATF 
(ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) sub-families (224).  AP-1 activity is induced by a 
plethora of physiological stimuli and environmental insults.  In turn, AP-1 regulates a wide range 
of cellular processes, including cell proliferation, death, survival and differentiation. The 
induction of AP-1 by pro-inflammatory cytokines and toxic stress is mostly mediated by the JNK 
and p38 MAPK cascades (225).  Once activated, the JNKs translocate to the nucleus (226), 
where they phosphorylate c-Jun and thereby enhance its transcriptional activity (227).  AP-1 
activity induced by nickel compound is varied in cells.  Although NF-κB activation by nickel 
compounds was observed in mouse fibroblasts (3T3) and human bronchoepithelial cells (BEAS-
2B), nickel treatment did not induce any activation of AP-1 in the same cells (228).  In human 
airway epithelial cells, however, nickel-induced IL-8 expression was shown to be dependent on 
AP-1 activation through an oxidant-independent pathway.  As a contact sensitizer, nickel sulfate 
activates the transcription factors NF-κB and AP-1 and increases the expression of nitric oxide 
synthase in a skin dendritic cell line (229).   
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In this study, my data indicate that NF-IL6 is also an important element upstream of the NF-κB 
site that mediates NiSO4 and MALP-2-induced upregulation of IL-6 gene transcription.  These 
findings suggest that NiSO4 and MALP-2 induced IL-6 gene expression is controlled by multiple 
transcription factors including NF-κB, AP-1 and NF-IL6.  Since transcriptional factor interaction 
may also be involved in the MALP-2 and nickel sulfate co-exposure, it seems important to study 
the IL-6 promoter with mutations in multiple sites to provide better information for studying this 
unique synergistic interaction in the future. 
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 4. DISCUSSION 
 
Experimental studies on the toxicologic effects of air pollutants primarily utilize exposure to 
single agents, while the real exposures in our normal life are rarely restricted to single stressful 
stimuli.  The demonstration of biologic effects of single agents frequently requires the use of 
pollutant exposures at concentrations in great excess of those found in ambient atmospheres, 
thereby making the relevance of the experimental studies difficult to extrapolate to the human 
conditions.  Recognizing this, an increasing number of inhalation studies are using more 
complex exposures to lower concentrations in order to mimic real world conditions (230;231).  
In this study, I first successfully established an in vitro model to demonstrate the synergistic 
interaction between mycoplasma live infection and ROFA particle in producing cytokine IL-6 in 
HLF.  Later this model was extended into the synergistic interaction between nickel sulfate and 
toll-like receptor 2 agonist MALP-2 in IL-6 production.  Further studies demonstrated the 
importance of MAPK pathway involvement in the synergistic interaction between NiSO4 and 
MALP-2 and confirmed that several transcription factors like NF-κB and NF-IL6 played 
important roles in IL-6 production caused by Ni and MALP-2 co-exposure. However, lots of 
other possibilities still remain unknown and need further investigation. Here, I list some of the 
important issues that worth to be considered and studied in the future. 
 
4.1. Oxidative stress 
Mycoplasma and oxidative stress 
It has been postulated that mycoplasma induce oxidative stress within infected cells. The 
production of reactive oxygen molecules is considered one of the major mechanisms by which 
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 mycoplasmas produce cytotoxic effects.  Mycoplasmas have a respiratory chain lacking 
cytochromes, and therefore superoxide and H2O2 are produced in significant amounts. Although 
the evidence for superoxide dismutase (SOD) in mycoplasmas is controversial, most of the 
species studied appear to express SOD (232).  In normal human cultured cells, infection with M. 
pneumoniae causes a marked inhibition of intracellular catalase (233;234).  Detoxification of 
elevated levels of H2O2 depends mostly upon the GSH redox cycle, and oxidative damage to the 
cells can be partially inhibited by adding vitamin E, an antioxidant (235;236). This characteristic 
of Mycoplasmas, in particular those found in the bloodstream of HIV-infected individuals (M. 
fermentans and M. pirum), may contribute to the observed oxidative stress, which would 
indirectly help activate HIV replication and increase the percentage of apoptotic cells (237;238).  
This suggests that M. fermentans induced oxidative stress may play a role in pathogenecity.  
Also, the activation of respiratory burst via NAD(P)H oxidase on inflammatory and possibly 
other cells in response to infection may contribute to the oxidative burden in infected cells (239). 
 
ROFA and oxidative stress 
On the other hand, evidence has accumulated that part of the injury induced by ROFA might be a 
result of oxidative stress (240;241).  It has been reported that free radicals and aldehydes are 
generated after intratracheal instillation of ROFA in rats (242;243). In fact, oxidative stress is a 
central hypothetical mechanism for the adverse effects of PM10 (244;245) via transition metal 
catalyzed redox cycling (121;246), ultrafine particle surfaces (247) and organic components 
(248;249). Particle-derived oxidative stress may play a role in initiating and prolonging 
inflammation, as well as in causing genotoxic effects.  Since several of the components of PM10 
can generate oxidative stress, there is potential for additive or synergistic interaction between the 
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 components.  Evidence shows that there can be synergistic interactions between transition metals 
and ultrafine particles in causing oxidative stress and lung inflammation (66).  One mechanism 
by which oxidative stress from PM10 may induce the expression of proinflammatory mediators is 
via stimulation of intracellular signaling pathways that employ calcium (250;251).  Intracellular 
calcium acts as a key signaling mechanism which, through interaction with a number of proteins 
such as calmodulin and enzymes such as protein kinases, is able to regulate the activation of a 
number of key transcription factors. Such transcription factors include nuclear factor of activated 
T cells (NFAT) and NF-κB (252;253).  For this reason, the role of particle-induced oxidative 
stress in the calcium response was investigated using the antioxidants n-acetylcysteine and 
mannitol, both of which diminished the ultrafine carbon black-enhanced thapsigargin response 
(247).  However, this inhibition was not absolute, suggesting that the effect may not be solely 
due to oxidative stress. 
 
Since both M. fermentans and particulate matter, especially ROFA, which is rich in transition 
metals, can induce oxidative stress responsible for cell damage, it will be of interest to study the 
role of oxidative stress in the synergistic interaction between M. fermentans and ROFA in 
amplifying IL-6 production in HLF. 
4.2. MAP kinase pathway 
 
MAPKs are important targets for PM10, however, the mechanism by which ROFA activates these 
signaling pathways is not known.  One mechanism of ROFA-induced MAP kinase activation 
could be by the induction of an oxidative stress due to the high content of bioavailable metals, 
predominantly vanadium, iron and nickel.  In vivo study shows that at the cellular, biochemical, 
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 and functional levels, DMTU inhibition of ROFA-induced activation of pulmonary ERK1/2, 
supporting a role for oxidative stress in this response (148).  These results are consistent with a 
number of in vitro studies that have demonstrated the ability of oxidative stress generated by 
ROFA-associated metals to induce MAP kinases (174;175).  Another possible mechanism for 
ROFA-induced activation of pulmonary MAP kinases could be by the direct inhibition of 
tyrosine phosphatase activity as shown by Samet et al. using human bronchial epithelial cells 
(143;176).  ROFA has a high content of vanadium, a potent tyrosine phosphatase inhibitor that 
leads to disregulation of phosphotyrosine metabolism and persistent activation of mitogen-
activated protein kinase (MAPK) signaling cascades in human airway epithelial cells (176).  In 
vivo studies show that there was a pronounced inflammatory response to ROFA instillation and a 
marked increase in levels of P-Tyr and P-MAPKs present within the alveolar epithelium and in 
the inflammatory cells, while the airway epithelium showed a prolonged increase in the 
expression of P-ERK1/2 (161).  Compared to other major metals components in ROFA like V 
and Zn, Ni, however, does not show very robust phosphatase antagonism.  By itself Ni acts as a 
poor redox catalyst compare to Fe, Cu, or V, but its redox activity is increased by complex to 
various endogenous proteins (254).  Ni activates mitogen-activated protein kinase signaling 
cascades in different type of cells (159;164;165).  Nickel-induced oxidative stress plays an 
important role in the pathogeneicity of nickel related cell injury (255-257).  The induction of 
inflammatory mediators can be regulated by the activation of redox-sensitive transcription 
factors AP-1 and NF-κB stimulated in response to reactive oxygen species (ROS).  Both 
environmental and inflammatory cell-derived ROS can lead to increases in intracellular calcium, 
the activation and phosphorylation of the mitogen activated protein kinase (MAPK) family, 
including extracellular signal regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38 
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 kinase, and PI-3K/Akt via sensitive cysteine-rich domains and the sphingomyelinase-ceramide 
pathway, leading to increased gene transcription (258-260).  Activation of members of the 
MAPK family leads to the transactivation of transcription factors such as c-Jun, activating factor-
2 (ATF2), and cyclic AMP response element binding proteins (CREB)-binding protein (CBP) 
(174;258).  This eventually results in chromatin remodeling and expression of a battery of genes 
involved in inflammation, apoptosis, proliferation, transformation, and differentiation.  H2O2, an 
oxidant stress causing cell injury and morphological transformation of epithelial cells, induced 
phosphorylation and activation of ERK at concentrations associated with the development of 
apoptosis in RPM cells, NIH/3T3 cells, bovine tracheal myocytes, and PC-12 cells (261-263).  
Crocidolite asbestos induces the phosphorylation and activation of ERK proteins, but not of 
JNK1, in RPM cells (264).  All those suggest that ROFA-induced MAP kinase activation may be 
due to its oxidative stress effects.   
4.3. Toll-like receptors 
 
Another subject that can be investigated in the future is how the toll-like receptor family may be 
related to the interaction between MALP-2 and ROFA or nickel sulfate.  Toll is a Drosophila 
gene essential for ontogenesis and antimicrobial resistance.  Several homologues of Toll have 
been identified and cloned in vertebrates, namely Toll-like receptors (TLRs).  TLRs are 
structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and by 
extracellular leucine rich repeats.  Toll-like receptors (TLRs) function to recognize pathogen-
associated molecular pattern (PAMP) in mammals and play an essential role in the recognition of 
microbial components and activation of host defense. In response to microbial or environmental 
"danger" signals, represented by structural motifs not normally expressed by cells, Toll-like 
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 receptors mediate intracellular signaling that leads to inflammatory gene expression by recruiting 
and/or activating TLR-specific adapter molecules.  To date, four adapter proteins have been 
identified: MyD88, TIRAP/Mal, TRIF/TICAM-1, and TIRP/TRAM/TICAM-2. The interaction 
of the different TLRs with distinct combinations of adapter molecules creates a platform to 
which additional kinases, transacting factors, and possibly other molecules are recruited. These 
events ultimately lead to gene expression.  More than ten members of the TLR family can be 
found in a search of human and mouse public genome databases (265;266) and ten members 
(TLRs 1–10) have been cloned and sequenced (267-271).  
 
By far the most extensively characterized members of the TLR family are the proteins TLR-2 
and TLR-4. TLR-2 acts as a PAMP receptor for various microbial products, including 
peptidoglycan, bacterial lipoproteins, lipoarabinomannan (LAM), glycosylphosphatidylinositol 
lipid from Trypanosoma cruzi, and zymosan, a component of yeast cell walls (272-275).  TLR-2 
does not recognize these PAMPs independently, but rather functions as a heterodimer with either 
TLR-1 or TLR-6 (276). A dimer of TLR-1 and TLR-2 (TLR-1/TLR-2) appears to recognize 
bacterial lipopeptides, whereas a TLR-2 / TLR-6 dimer responds to mycobacterial lipopeptides.  
These lipopeptides differ in the number of acyl groups they contain, attesting to the specificity in 
recognition by different TLRs.  Lipoproteins are proteins containing lipid that is covalently 
linked to the NH2-terminal cysteines; they are present in a variety of bacteria, including Gram-
negative and Gram-positive bacteria and mycoplasmas.  TLR-2 mediates the responses to 
lipoproteins derived from M. tuberculosis, Borrelia burgdorfei, Treponema pallidium and 
Mycoplasma fermentans (277-279).  Most lipoproteins are triacylated at the NH2-terminal 
cysteine residue, but mycoplasmal macrophage-activating lipopeptide 2 (MALP-2) is only 
diacylated. TLR-2 null cells are unresponsive to all lipoproteins, whereas TLR-6 null cells are 
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 unresponsive to MALP-2 but responsive to other lipopeptides of bacterial origin (48).  
Coexpression of TLR-2 and TLR-6 is absolutely required for MALP-2 responsiveness since 
TLR-2 and TLR-6 cooperate to recognize MALP-2 and TLR-6 appears to confer the ability to 
discriminate between the NH2-terminal lipoylated structure of MALP-2 and lipopeptides derived 
from other bacteria (266).  Further investigation of TLR-2 and TLR-6 signaling is an important 
point for our future study since it is possible that alterations in TLR-2 expression or its signaling 
components by various environmental chemicals may facilitate the recognition and response to 
various microbial-derived components.  This would render the exposed cells more sensitive to 
the cell-activating inflammatory properties of normal flora of pathogens compared to the cells in 
the absence of chemical exposure.  The potential pitfall for this theory is that the effects observed 
with infection with live M. fermentans may be only partially TLR-2 dependent and additional 
TLRs may be involved.  If the role of TLR-2 in mycoplasma-induced effects turns out to be 
small, the downstream signaling mechanisms common to all TLRs should be investigated.  
Among the four adaptor proteins, MyD88 is a good approach since it represents a common 
signaling protein recruited to all TLRs and is required for subsequent protein interaction that lead 
to NF-κB activation. 
4.4. Metal interaction 
 
Another important issue to be discussed is the possible synergistic interaction between metals. 
ROFA does not contain significant amounts of organic components, but does contain relatively 
high quantities of transition metals.  Metals cannot be destroyed by combustion, but are 
redistributed throughout the solid exhaust material. V, Fe, Ni, Zn, Cu and Co are typically the 
metals found at highest concentrations and appear to play a substantial role in acute toxic effects 
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 on alveolar epithelial cells (176;280).  Three metals, namely, Fe, V, and Ni, are present in the 
largest quantities, and the amount of each metal can vary depending on the source of the 
particles.  Although particulate matters contain a mixture of chemicals, most toxicology studies 
investigate adverse responses to individual chemicals, not mixtures of chemicals.  The traditional 
assumption, in the absence of further information, has been that if the individual chemicals have 
the same health end-point, then the chemical components of a mixture have mutually 
independent effects and the toxic response to multiple chemicals is additive.  But in fact, some 
metal-metal interaction induces a synergistic effect related to health problems.  Since our present 
study found that nickel component in ROFA is important to the end point of inducing 
proinflammatory cytokine release, we will discuss some metal-metal interactions related to 
nickel. 
 
4.4.1. Nickel and Iron 
 
In some ROFA preparation, nickel content can comprise up to 35% of the amount of all metals 
(149;150), and it was recently shown that it is water-soluble nickel that is responsible for the 
majority of pulmonary injury caused by ROFA (158).  Moreover, pulmonary inflammation 
induced by ROFA was reproduced by intratracheal instillation of a mixture of soluble forms of 
nickel (132).  Iron is another important PM component and some of the pathological effects after 
PM inhalation may be due to reactive oxygen species produced by iron-catalyzed reactions.  For 
example, it has been suggested that iron could induce IL-8 production in A549 cells due to 
reactive oxygen species induction (132;281).  Thus, it is clear that either iron or nickel alone can 
produce biological effects.  However, there are very few investigations related to the effects of 
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 co-exposure of these two metals.  Recently it was found that nickel is an activator of heme 
oxygenase, the rate-limiting enzyme in heme catabolism.  Ni2+ may also regulate and increase 
iron absorption through a mechanism that simulates hypoxic conditions in the tissues (282).  But 
nickel can induce different signaling pathways with or without interference with iron metabolism 
and in some cases the excess of iron in PM could inhibit the effects of nickel (75). 
 
4.4.2. Nickel and Cobalt 
 
 Nickel and cobalt are two metals that are frequently found together in workplaces such as mines, 
smelters, and cobalt alloys (283).  For example, cobalt is a byproduct of nickel ore processing, 
cobalt alloys often include nickel (284), and cobalt shortages have forced hard metal 
manufacturers to substitute pure cobalt with mixtures of nickel and cobalt in the process of 
sintering (285).  No epidemiology studies have established a link between inhalation of cobalt 
and lung cancer in humans, although cobalt can cause allergic asthma or ‘work-related wheeze’, 
which may lead to interstitial fibrosis (284).  Of note is the fact that cross-reactivity between Ni 
and Co is often observed in workers with “hard metal asthma”.  In animal models, cobalt sulfate 
(CoSO4) aerosol can induce alveolar and bronchiolar tumor formation and can cause reductions 
in lung compliance (286).  Although studies such as those mentioned above have investigated the 
toxicity of nickel and cobalt alone, little is known about the toxic effects of mixtures of nickel 
and cobalt on most tissues and organs.  But still, some studies suggest that inhalation exposure to 
mixtures of nickel and cobalt chlorides affect certain aspects of pulmonary morphology in a 
synergistic manner (287;288).  
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4.4.3. Nickel and Vanadium  
 
An in vivo study of the effects of ROFA-associated transition metals demonstrated that intra-
tracheal instillation of  V caused  immediate effects, while instilled Ni was responsible for a 
delayed response (64).  Moreover, certain interactive effects occurred when these metals were 
administered in combination, including an apparent synergism between Ni and V and an 
attenuating effect from Fe.  Specifically, Ni exacerbated the immediate response to V in a more 
than additive manner, while Fe coexposure reduced the effects of both V and Ni + V instillation. 
Although the mechanisms of this synergy is not very clear, it is conceivable that at low lung 
burdens, Ni and / or V could produce oxidative stress that would not pose a significant problem 
for the defense and repair pathways of a healthy cell (63).  However, generation of radicals by V 
could exacerbate the outcome of Ni-induced cell cycle arrest.  Either or both of these mechanisms 
could play a role in causing the synergistic increases in pulmonary inflammation, bradycardia, 
hypothermia, arrhythmogenesis, and fibrinogen levels.  These results indicate a possible 
synergistic relationship between inhaled Ni and V, and provide insight into potential interactions 
regarding the toxicity of PM-associated metals (63). 
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5. SUMMARY AND FUTURE DIRECTION 
 
In the present study, a new discovery is the synergistic interaction between M. fermentans and 
ROFA in producing proinflammatory cytokine IL-6 release by human lung fibroblast cells.  This 
discovery was later extended to include the interaction between M. fermentans-derived 
macrophage activating lipopeptide (MALP-2) and transition metal component nickel sulfate to 
stimulate IL-6 cytokine production to an extent greater than the additive sum of the responses to 
each stimulus alone.  Part II of the thesis focuses on the potential MAP kinase pathway 
involvement in the synergistic interaction between the two stimuli.  The very first study in this 
part is the time course of NiSO4 and MALP-2 interaction which suggested that one stimulus 
potentiates another one to inducing IL-6 release in later time points.  Later on, it was confirmed 
that NiSO4 pretreatment facilitated MALP-2-induced IL-6 production and this potentiating 
effects is partially abolished by MER/ERK1/2 inhibitor.  Even though NiSO4 induced ERK1/2 
and JNK phosphorylation, it seems only ERK phosphorylation is related to NiSO4’s potentiation 
effects.  In the third part of this study, IL-6 gene regulation was investigated in order to explore 
the possible mechanism of this unique synergistic interaction.  Studies show that NF-κB is very 
important to the basal IL-6 gene expression in human lung fibroblasts, while NF-IL6 is important 
for the interaction between NiSO4 and MALP-2.  However, the same degree of synergistic 
interaction between NiSO4 and MALP-2 seen with IL-6 protein is not observed at gene 
expression level, which suggests other mechanisms are likely involved.   One of the possibilities 
is that either stimulus alone or together cause alterations in IL-6 mRNA stability.  Other 
possibilities include the involvement of other signaling pathway kinases like MyD88 or TRAF6 
that are separate from MAPK pathway since blocking MAPK pathway can not fully absolutely 
99 
 abolish the synergistic interaction between NiSO4 and MALP-2.  Regulation of the expression of 
TLR family members is another issue to be addressed.  It is possible that NiSO4 or other metals 
facilitates MALP-2-induced IL-6 or other cytokine production by increasing toll-like receptor 
expression or function and need to be studied.  Oxidative stresses induced by ROFA and M. 
fermentans may also play an important role in the interaction.  Also, it will be important to 
develop an animal model that allows the in vivo study of the possible pulmonary injury / 
inflammation repair processes in response to the co-exposure of microbial and chemical stress.  
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